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FORMULATION AND DISSOLUTION OF POLYMER STRIP FILMS FOR THE 
DELIVERY OF POORLY WATER-SOLUBLE DRUG NANOPARTICLES 
by 
Scott Matthew Krull 
Polymer films have emerged as a promising platform for delivery of pharmaceutical 
products in recent years due to simplified processing, greater flexibility, and improved 
patient compliance over traditional solid dosage forms. However, the large majority of 
efforts have focused on incorporation of water-soluble drugs. The objective of this 
dissertation is to explore the robustness and versatility of the strip film platform for 
delivery of poorly water-soluble drug nanoparticles to ultimately develop a predictive 
model for drug release from such films. 
The robustness of the polymer strip film platform to successfully deliver a variety 
of poorly water-soluble drug nanoparticles without the need for surfactant is 
demonstrated first. Drug nanoparticle-loaded films are prepared with and without 
surfactant for five distinct poorly water-soluble drugs. Fast release is achieved for films 
made with all five drugs despite differences in water solubility, even in the absence of 
surfactant, with minimal differences in film quality and properties. Next, various 
formulation aspects are investigated for their impact on film quality and performance. In 
one study, three plasticizers at three different concentrations are incorporated into drug 
nanoparticle-loaded polymer films. A depression in glass transition temperature is 
observed with increasing plasticizer concentration, along with a corresponding decrease 
in film tensile strength and increase in film elongation. However, the type and amount of 





that film mechanical properties can be effectively manipulated by varying plasticizer 
concentration with minimal impact on drug release. In another study, three different film-
forming polymer molecular weights at three different viscosity levels are used to prepare 
films containing poorly water-soluble drug nanoparticles. No statistical differences in 
film tensile strength or elongation at break are observed between films regardless of 
polymer molecular weight despite requiring up to double the time to achieve 100% drug 
release, suggesting that film-forming polymer molecular weight can be used to 
manipulate drug release with little impact on film mechanical properties. The maximum 
practical drug loading in films is also investigated to address the misconception that strip 
films are limited to very low dosages. Films made using two film-forming polymer 
molecular weights are prepared with different concentrations of poorly water-soluble 
drug nanoparticles by varying the drug loading in the nanosuspension from which the 
nanoparticles are taken and the polymer-to-nanosuspension mixing ratio. All films up to 
50 wt% drug loading show good content uniformity and drug nanoparticle 
redispersibility, suggesting that high drug loading can indeed be achieved in polymer 
films, although films tend to become less elastic and more brittle as drug loading 
increases above 40 wt%. Finally, a mathematical model is developed to predict the rate of 
drug release from polymer films containing drug particles based on first principles. 
In summary, various formulation aspects of the polymer strip film platform are 
investigated for delivery of poorly water-soluble drug nanoparticles and a mathematical 
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 Background Information 1.1
Polymer strip films have become an increasingly popular method of drug delivery in 
recent years. In addition to offering a larger surface area for faster disintegration and 
dissolution (Dixit and Puthli, 2009) as well as the ability to circumvent the first pass 
metabolism in buccal applications (Averineni et al., 2009), films also offer several 
formulation, manufacturing, and consumer-based advantages over more traditional solid 
dosage forms. Noteworthy manufacturing advantages include inherently continuous 
processing and flexible, cost-effective scale-up (Hoffmann et al., 2011; Zhang et al., 
2014). Consumers, particularly pediatric, geriatric, and dysphagic patients, have 
demonstrated a higher degree of compliance for film-based pharmaceuticals (Dixit and 
Puthli, 2009). Commercial feasibility of thin films as a drug delivery platform has been 




 (simethicone) from Novartis
®
 
for pain or discomfort caused by excessive gas, Zuplenz
®
 (ondansetron) from MonoSol 
Rx
®
 for nausea and vomiting caused by radiation therapy, RapidFilms
®
 (donezepil) from 
Labtec
®
 GmbH for treatment of dementia caused by Alzheimer’s disease, and Suppress™ 
Cough Strips (dextromethorphan/menthol) from InnoZen
®
 Inc. to suppresses coughing due 
to minor throat and bronchial irritation. Recent developments have also explored more 
versatile applications for drug-loaded polymer films, including the gastro retentive 
Accordian Pill™ from Intec Pharma Ltd., as well as rolled or compressed multi-layer 




common is their use of water-soluble drugs, which are easiest to formulate with for fast 
dissolution and homogeneous drug distribution. Despite the growing number of poorly 
water-soluble drug candidates in the pharmaceutical industry in recent years (Lipinski, 
2002), they have yet to appear on the market in the strip film format due to their limited 
dissolution and bioavailability. 
While initial studies and commercial applications for pharmaceutical films 
focused on incorporation of water-soluble drugs (Borges et al., 2015a; Dave et al., 2014; 
Dixit and Puthli, 2009; Garsuch and Breitkreutz, 2010), recent studies have begun to 
explore the potential for incorporation of poorly water-soluble drugs into polymer strip 
films. Films are believed to be an ideal delivery form for the growing library of poorly 
water-soluble drugs in part because they offer larger available surface area, allowing for 
rapid disintegration and dissolution, even in the oral cavity, which cannot be matched in 
traditional dosage forms (Dixit and Puthli, 2009). Although this is commonly done via 
hot melt extrusion (Kumar et al., 2014; Visser et al., 2015) or organic solvent casting 
(Prodduturi et al., 2005), both may lead to drug instability and drug loading limitations in 
the resulting films (Kipp, 2004). In light of these issues, various particle engineering 
techniques have also been employed to improve poorly water-soluble drug dissolution 
rate for incorporation into strip films. These include wet stirred media milling (WSMM) 
(Davé et al., 2014; Krull et al., 2016b; Sievens-Figueroa et al., 2012a; Susarla et al., 
2015; Susarla et al., 2013) and high pressure homogenization (Lai et al., 2015; Shen et 
al., 2013) to reduce drug particle size, as well as liquid antisolvent precipitation (Beck et 
al., 2013) and melt emulsification (Bhakay et al., 2016) to produce drug nanoparticles via 




small crystalline drug particles into polymer films can eliminate the need for organic 
solvents, offer predictable form, size, and distribution of drug particles, and most 
importantly, result in fast release for BCS (Biopharmaceutics Classification System) class 
II drugs. In addition, these studies demonstrate that the improvement in dissolution rate 
from films is even more pronounced when compared to those of physical mixtures and 
compacts of identical composition. The fast and predictable release of poorly water-
soluble drugs offered by the film format is expected to be crucial, as agglomeration of 
primary drug particles upon release may lead to slower dissolution and limited 
bioavailability (de Villiers, 1996). This issue has been identified in other nanoparticle-
based dosage forms, where loss of large surface area was a major obstacle to achieving 
expected gains in dissolution enhancement (Bhakay et al., 2014a; Bhakay et al., 2014b; 
Bhakay et al., 2013). 
With the groundwork in place for strip films as a stable and robust platform for 
poorly water-soluble drug delivery, attention has shifted from process development to 
intelligent formulation design. One of the most intriguing aspects of the strip film format 
resides in its versatility. Strip films benefit from access to a wide variety of usable 
excipients, including film-formers and plasticizers, which can be used to control various 
properties of the films without sacrificing the integrity of the format (Borges et al., 
2015b; Dixit and Puthli, 2009). However, little is known about how these critical material 
attributes (CMAs) impact properties of drug particle-laden films, such as drug particle 







Pharmaceutical strip films have garnered significant attention thanks to improved patient 
compliance, cost-effective scale-up and the potential for continuous manufacturing. The 
ability to stabilize and release drug nanoparticles makes strip films an ideal platform for 
the delivery of poorly water-soluble drugs. However, this capability has only been 
demonstrated for a select few BCS class II drugs in combination with specific excipients. 
Due to the novelty of the platform, scant information exists on how the components of 
the film, most notably drug and polymer, impact various film properties and performance 
of the final dosage. In light of this, it is the ultimate objective of this work to demonstrate 
the robustness and predictable properties of strip films loaded with poorly water-soluble 
drug nanoparticles such that the nanoparticles are physically stabilized and released in the 
absence of aggregation so that their enhanced bioavailability is maintained upon delivery. 
 
 Dissertation Outline 1.3
This dissertation work is presented in seven chapters. Chapter 1 begins with a review of 
relevant background concepts and literature, followed by the objective and outline of the 
dissertation. Chapter 2 examines the ability of the strip film format to effectively stabilize 
and deliver a variety of poorly water-soluble drug nanoparticles with and without the aid 
of a surfactant. Chapter 3 investigates the capability of manipulating the mechanical 
properties of poorly water-soluble drug nanoparticle-laden films by adjusting the type 
and amount of plasticizer used without significantly impacting the rate of drug release 
during dissolution. Chapter 4 explores the ability to adjust the release rate of poorly 




film-forming polymer with limited impact on film mechanical properties. Chapter 5 
studies the potential for high loadings (40-50 wt%) of poorly water-soluble drug 
nanoparticles in strip films and the effect of high drug loading on film properties. Chapter 
6 presents a numerical first principles model for the dissolution of polymer films loaded 
with poorly water-soluble drug particles, which incorporates drug particle dissolution and 
diffusion, solvent imbibition, film swelling, and polymer erosion. Chapter 7 provides an 







2 EFFECT OF DRUG AND SURFACTANT___ 
 
 Introduction 2.1
Although previous studies have shown the potential of the strip film format, they were 
limited by a small selection of drugs, poor content uniformity, and reliance on surfactant. 
Sievens-Figueroa et al. (2012a) investigated three poorly water-soluble drugs and 
demonstrated the feasibility of using HPMC-based thin films for delivery of drug 
nanoparticles, but their work suffered from use of long drying times and relatively low 
film precursor viscosities, all of which are considered to adversely impact drug content 
uniformity, which was not reported in their work. Beck et al. (2013) considered liquid 
anti-solvent crystallization of only one poorly water-soluble drug and followed similar 
formulation and manufacuring protocols, also neglecting to discuss the important topic of 
drug content uniformity. Although Susarla et al. (2013) used only one poorly water-
soluble drug, their work was the first to demonstrate that film drying via combined 
conduction and convection leads to commercially feasible faster drying times, and more 
importantly, showed that employing higher viscosity polymeric film precursors leads to 
improved content uniformity. Unfortunately, all of these studies were limited because 
content uniformity was only assessed for one drug, and more importantly, surfactants 
were used to achieve drug particle stability and fast release. Consequently, the previous 
studies did not demonstrate the robustness of the process for a wide variety of BCS class 
II drugs and polymer strip films as a surfactant-free drug delivery platform with very 




Poorly water-soluble drugs exhibit limited dissolution and bioavailability, both of 
which are known to be significantly enhanced by the introduction of surfactant through 
either micellar solubilization of the drug particles (Ghebremeskel et al., 2007; Jamzad 
and Fassihi, 2006; Jinno et al., 2000) or improvement of wettability–redispersion 
(Bhakay et al., 2014a). One of the most common techniques used to improve the 
dissolution and bioavailability of these drugs involves particle size reduction, which 
increases the surface area-to-volume ratio of the drug particles, significantly enhancing 
their ability to solubilize when exposed to aqueous media (Hu et al., 2004; Thorat and 
Dalvi, 2012). Surfactants serve a crucial role as stabilizers in many particle size reduction 
processes, including wet stirred media milling (WSMM), in which they act to prevent 
freshly milled nanoparticles from aggregating back together during the milling process 
and storage, particularly in combination with nonionic steric stabilizers (Bilgili and 
Afolabi, 2012; George and Ghosh, 2013; Kipp, 2004; Van Eerdenbrugh et al., 2009). 
Thus, in general, for certain drugs and applications, sufficient dissolution and 
bioavailability upon delivery is impossible without the use of surfactants or other 
solubilizers/dispersants. For example, it is well known that redispersibility of poorly 
water-soluble drugs from spray dried and fluid bed coated composites is drastically 
improved by incorporation of surfactant, without which the dissolution enhancement due 
to nanoparticles could be insignificant (Balakrishnan et al., 2004; Bhakay et al., 2014a; 
Wong et al., 2006). When surfactants are not used, other dispersants such as mannitol 
may be used. However, even sufficiently large amounts of mannitol, which reduce the 




comparable to the use of surfactant (Azad et al., 2015; Bhakay et al., 2014b; Knieke et 
al., 2015). 
Previous studies have shown that, without any additional dispersants, complete 
dissolution of poorly water-soluble drug nanoparticles from 100 µm-thick HPMC based 
films can be achieved within 20 min, but only when a surfactant-based dissolution 
medium was used (Sievens-Figueroa et al., 2012a; Susarla et al., 2013). Both studies also 
started with drug nanosuspensions stabilized by a surfactant, thus suggesting the need for 
surfactant for dissolution enhancement even from the strip film format, which uses a high 
polymer concentration or polymer-to-drug ratio. These studies failed to investigate this 
important feature of the strip film based dosage form, namely, the use of a relatively high 
concentration of polymers, leading to high viscosity (>> 1,000 cP) film precursor 
suspensions that ensure a flexible, uniform film matrix. This feature is unique to strip 
films and may not be easily provided by other nanocomposite dosage forms such as core-
shell nanocomposites (Bhakay et al., 2013) or spray-dried nanocomposites (Azad et al., 
2015). Hence, an important question arises whether or not the relatively high polymer 
concentration required for film formation is sufficient to stabilize the drug nanoparticles 
without the use of surfactant. If the answer is positive, it can also help negate several 
disadvantages of the use of surfactant. For example, use of surfactant in suspensions can 
promote physical instability and particle growth via Ostwald ripening, especially if the 
concentration of surfactant is above the critical micelle concentration (Cerdeira et al., 
2010; Verma et al., 2011). In addition, surfactant is also known to cause gastric and 




In addition to the role of surfactant, interaction between polymer and drug is 
known to significantly influence drug particle stability as well as release from solid 
dosage forms. Strong polymer–drug interaction in solid dispersions and suspensions has 
been shown to promote particle stability (Huang et al., 2008; Karavas et al., 2007). 
However, while these interactions have been shown to influence various film properties, 
such has only been classified in solvent cast films incorporating amorphous drug. Nair et 
al. (2001) observed hydrogen bonding between drug and polymer via Fourier transform 
infrared (FTIR) spectroscopy in polyvinylpyrrolidone films across multiple drugs. 
Puttipipatkhachorn et al. (2001) noted slower dissolution from salicylic acid films than 
theophylline films, likely due to greater interaction between salicylic acid and chitosan, 
the film-former, than was observed with theophylline. Wu and McGinity (1999) found 
that introducing ibuprofen and methylparaben to Eudragit RS 30 D films resulted in a 
plasticizing effect and Lin et al. (1995) observed a similar trend upon loading piroxicam 
into Eudragit E films, noting a shift in characteristic IR peaks for piroxicam indicative of 
interaction with Eudragit E. However, none of these studies addresses polymer 
interaction with drug nanoparticles, let alone the ability for these interactions to 
effectively prevent drug particle aggregation. 
This chapter demonstrates that surfactant-free polymer strip films loaded with 
poorly water-soluble drug nanoparticles have excellent content uniformity and retain the 
same advantages as films containing surfactant-stabilized drug nanoparticles, including 






 Experimental Procedures 2.2
2.2.1 Materials 
Fenofibrate (FNB; Jai Radhe Sales, Ahmedabad, India), griseofulvin (GF; Letco Medical, 
Decatur, AL), naproxen (NPX; Medisca, Plattsburgh, NY), phenylbutazone (PB; 
Medisca, Plattsburgh, NY), and azodicarbonamide (AZD; Pfaltz & Bauer, Waterbury, 
CT) were selected as model BCS class II drugs. Physicochemical properties of the drugs 
are shown in Table 2.1 (Verschueren, 2001; Yalkowsky, 2003). Low molecular weight 
(MW) hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV, MW            
~ 14,000, The Dow Chemical Company, Midland, MI) was used as a stabilizer and film 
former. Sodium dodecyl sulfate (SDS; Fisher Scientific, Pittsburgh, PA) was also used as 
a stabilizer for formulations containing surfactant. Glycerin (Sigma-Aldrich, Saint Louis, 
MO) was used as a film plasticizer. Drug particle size was reduced via WSMM as 
described in Sub-section 2.2.2.1. All other materials were used without further 
processing. 
Table 2.1 Physicochemical Properties of Drugs Incorporated into Polymer Films 
2.2.2 Preparation Methods 
2.2.2.1 Preparation of Drug Nanosuspensions. Surfactant-free drug nanosuspensions 
were produced via WSMM utilizing a Netzsch mill (Microcer, Fine particle technology 
Drug 
Solubility in water 




(ºC) log P 
FNB   0.8 360.8   81   5.3 
GF   8.6 352.8 220   2.2 
NPX 15.9 230.3 153   3.2 
PB 34.0 308.4 105   3.2 




LLC, Exton, PA) according to previously established methods (Bilgili and Afolabi, 2012; 
Monteiro et al., 2013). HPMC-E15LV served as a stabilizer. All suspensions were milled 
for 120 min and consisted of 10% drug (on a w/w basis wrt water) dispersed in a 
stabilizer solution of 2.5% HPMC (on a w/w basis wrt water). 0.5% SDS (on a w/w basis 
wrt water) served as an additional stabilizer for the corresponding surfactant-containing 
formulations. 
2.2.2.2 Preparation of Film Precursor Suspensions. HPMC polymer solutions 
were prepared according to Dow
®
 protocol (Susarla et al., 2013). The starting polymer 
concentration was chosen to ensure the mixture of polymer solution and nanosuspension 
had sufficiently high viscosity (~8000 cP) to produce a uniform, good quality film 
(Susarla et al., 2013). Corresponding amounts of HPMC-E15LV and glycerin, selected 
for their ability to form quality films loaded with drug nanoparticles (Sievens-Figueroa et 
al., 2012a), were added to water at 90 ºC such that the composition of the polymer 
solution was 17% HPMC and 5% glycerin (on a w/w basis) and allowed to cool to room 
temperature under continuous stirring. The polymer solution was then shear mixed with 
the drug nanosuspensions in a 2:1 ratio by mass at approximately 120 rpm for 6-12 h 
using a motor driven dual-propeller mixer (McMaster-Carr, USA) (Susarla et al., 2013). 
In the case of placebo formulations X1 and X2, the appropriate drug-free stabilizer 
solution was used instead of the drug nanosuspension. The compositions of the resulting 
polymer–nanosuspension mixtures, hereafter referred to as film precursor suspensions, 





Table 2.2 Composition of Film Precursor Suspensions Cast to Form Strip Films Loaded 










F1 FNB 3.0 12.1 3.3 0.00 
F2 FNB 3.0 12.1 3.3 0.15 
G1 GF 3.0 12.1 3.3 0.00 
G2 GF 3.0 12.1 3.3 0.15 
N1 NPX 3.0 12.1 3.3 0.00 
N2 NPX 3.0 12.1 3.3 0.15 
P1 PB 3.0 12.1 3.3 0.00 
P2 PB 3.0 12.1 3.3 0.15 
A1 AZD 3.0 12.1 3.3 0.00 
A2 AZD 3.0 12.1 3.3 0.15 
X1 N/A 0.0 12.1 3.3 0.00 
X2 N/A 0.0 12.1 3.3 0.15 
 
2.2.2.3 Preparation of Polymer Films Containing Drug Nanoparticles. For each 
film, approximately 8-9 g of film precursor suspension was manually cast onto a stainless 
steel substrate at room temperature using a casting knife (Elcometer, MI). The casting 
thickness was fixed at 1,000 µm and the final dimensions of the films were 
approximately 8 cm × 9 cm. The wet films were then dried at 50 ºC in the third zone of a 
Lab-Cast Model TC-71LC Tape Caster (HED International, NJ) in batch mode under 
laminar air flow for a period of 1 h (Davé et al., 2014). The dry films were peeled from 
the substrate and stored in individual sealed plastic bags at room temperature for 
characterization within days of preparation. 
2.2.3 Characterization Methods 
2.2.3.1 Viscosity of Film Precursor Suspensions. The apparent shear viscosity 
of film precursor suspensions was measured using an R/S-CC+ Coaxial Cylinder 




controlled coaxial cylinder (CC25) and Lauda Eco water jacket assembly (Lauda-
Brinkmann LP, Delran, NJ) for temperature control. Film precursor suspensions were 
subjected to a low shear rate program (0-20 s
-1
) at 25 ± 0.5 ºC to measure low shear 
viscosity. Raw data was analyzed using Rheo 3000 software (Brookfield Engineering, 
Middleboro MA). All experiments were performed a minimum of four times. 
2.2.3.2 Drug Particle Size after Milling and Redispersed from Films.      The size 
distribution of drug particles was measured both in suspension immediately after milling 
and redispersed from films using a Coulter LS 13320 Laser Diffraction Particle Size 
Analyzer (Beckman Coulter, Miami, FL). In order to measure particle size after milling, a 
1.2 ml sample was removed from the holding tank of the mill, dispersed into 4 ml of the 
respective stabilizer solution via pipette and vortex mixed at 1500 rpm for 1 min prior to 
sizing.  
The nanoparticle stabilization imparted by the films is assessed based on their 
ability to preserve drug particle size from the suspension through the process of film 
formation and subsequently upon redispersion in water. To assess drug nanoparticle 
redispersibility, samples of films, cut using circular punches of ~0.71 cm
2
 in area, were 
vortex mixed in 3 ml of deionized (DI) water for 3-5 min. Additional punched film 
samples were required for drugs with higher solubility in order to prevent any significant 
fraction of drug particles from dissolving in the 110 ml of DI water in the sample cell 
prior to particle sizing (1 for FNB, 3 for GF, 7 for NPX, 10 for PB and AZD).  
2.2.3.3 Determination of Drug Content and Uniformity in Films. Ten circular 
samples ~0.71 cm
2
 in area were punched from each film and dissolved in 250 ml of      




Scientific Evolution 300 UV-Vis spectrophotometer (Thermo Fisher Scientific Inc., MA) 
was used to measure the UV absorbance of each sample using the appropriate wavelength 
of maximum absorbance for each drug (290 nm for FNB, 291 nm for GF, 272 nm for 
NPX, 264 nm for PB, and 245 nm for AZD) and the concentration of each sample was 
calculated using a corresponding calibration curve. The average drug weight per unit area 
of the film, average weight percentage of the drug in the film, and relative standard 
deviation (RSD) of these two measures were calculated for each set of 10 samples. 
2.2.3.4 Film Mechanical Properties. Film mechanical properties were measured 
using a TA-XT Plus Texture Analyzer (Stable Microsystems, UK). Rectangular film 
strips with dimensions of 50 mm × 15 mm were held between two grips and stretched at a 
constant speed of 1 mm/s until the point of tensile failure. Tensile strength (TS), yield 
strength (YS), Young’s modulus (YM), and percent elongation at break (EB) were 
computed from the resulting stress vs. strain data. Data represents an average of four 
strips. 
2.2.3.5 Scanning Electron Microscopy (SEM). A field emission scanning electron 
microscope (FESEM) LEO1530VP GEMINI (Carl Zeiss, Inc., Peabody, MA) was used 
to examine the composite structure in the film and to observe the presence of any drug 
aggregates within the films. A small sample of the film was placed on an aluminum stub 
using carbon tape and carbon coated using a sputter coater (Bal-Tec MED 020 HR, Leica 
Microsystems, Wetzlar, Germany) prior to imaging. The cross sectional image of all 




2.2.3.6 Thermogravimetric Analysis (TGA). Thermogravimetric analysis (TGA) 
was performed using a TGA/DSC1/SF Stare system (Mettler Toledo, Inc., Columbus, 
OH). A ~2 mg film sample was placed in a ceramic crucible and heated under nitrogen 
flow from 25 ºC to 150 ºC at a constant rate of 10 ºC/min, held at 150 ºC for 15 min, 
heated to 250 ºC at a rate of 10 ºC/min, and finally cooled back to 25 ºC at a rate of       
10 ºC/min. 
2.2.3.7 Fourier Transform Infrared (FTIR) Spectroscopy. FTIR spectra were 
measured for each film as well as pure as-received drug powders and placebo films 
containing no drug using a Fourier Transform Infrared Spectrometer (Nicolet 560 FTIR) 
with an attached Attenuated Total Reflectance (ATR) accessory and a single reflection 
ZnSe crystal (MIRacle, Pike Technologies). Samples were measured within the range 
from 600 to 4,000 cm
-1
. The spectral resolution of FTIR spectra was set to 4 cm
-1
 and 
compared to the background interferogram. Reported final spectra are an average of    
100 scans. 
2.2.3.8 Raman Spectroscopy. Raman spectroscopy was carried out with an EZ 
Raman-L system (SN: LE-178155, Enwave Optronics, Inc.) equipped with a fiber optic 
probe (785 nm laser, 250 mW, working distance 6 mm). The spectral range was between 
100 and 3,300 cm
-1
. Raman spectra were taken for an average of 3 scans, each 10 s long 
and totaling 60 s in scanning time. 
2.2.3.9 Flow-through Cell Dissolution (USP IV).  A flow-through cell 
dissolution apparatus (USP IV; Sotax, Switzerland) with cells of 22.6 mm internal 




nanoparticle-loaded polymer films (Sievens-Figueroa et al., 2012b). Previous work has 
shown that use of 0.1 µm filters instead of 0.2 µm filters had no significant impact on the 
release profiles of films containing drug nanoparticles with mean diameter as low as    
160 ± 30 nm (Kakran et al., 2010; Sievens-Figueroa et al., 2012a; Sievens-Figueroa et al., 
2012b). Circular film samples ~0.71 cm
2
 in area were secured horizontally inside the 
cells within 5 g of 1 mm glass beads. Cell temperature was maintained at 37.0 ± 0.5 ºC 
and dissolution media was circulated at a flow rate of 16 ml/min. Two dissolution media 
were employed for comparison, each using 100 ml per cell: 5.4 mg/ml SDS solution 
(USP recommended for GF, for which these methods were established)               
(Sievens-Figueroa et al., 2012a; Sievens-Figueroa et al., 2012b; Susarla et al., 2013) and 
DI water as a surfactant-free medium (pH 6.7). The average drug release across six 
samples from each film was plotted as a function of time. 
 
 Results and Discussion 2.3
2.3.1 Precursor Suspension Viscosity 
Viscosity of the film precursor suspension has been shown to have a significant impact 
on the content uniformity of the resulting dry film. Susarla et al. (2013) demonstrated that 
use of higher viscosity precursors generally led to more uniformly distributed drug 
nanoparticles in films. Table 2.3 shows the apparent shear viscosity of all film precursor 
suspensions at low shear rate (2.2 s
-1
) to mimic conditions of film casting. With the 
exception of FNB, surfactant-free film precursor suspension viscosities ranged from 
about 9,000-11,000 cP while those of SDS formulations ranged from 11,000-13,000 cP. 




followed by NPX (+28%), PB (+11%), and AZD (+8%), while GF (-3%) showed no 
statistical difference (p > 0.05). 
Table 2.3 Low Shear (2.2 s
-1
) Viscosity of FNB, GF, NPX, PB and AZD Film Precursor 
Suspensions at 25 ºC 
Formulation Viscosity (cP) 
F1   7,470 ± 320 
F2 10,340 ± 580 
G1 11,010 ± 440 
G2 10,640 ± 410 
N1 10,020 ± 570 
N2 12,840 ± 550 
P1 10,030 ± 150 
P2 11,180 ± 910 
A1 12,010 ± 150 
A2 12,920 ± 360 
 
Viscosity increases with increasing surfactant concentration have also been 
reported in dilute polymer solutions. Brackman (1991) observed a general increase in 
viscosity and viscoelasticity of aqueous poly(ethylene oxide) solutions (< 30 cP) as SDS 
concentration was increased and Kulicke et al. (1998) observed a viscosity increase with 
increasing SDS concentration (up to 13 mM) for weakly hydrophobic 0.5% (w/w) HPMC 
solutions. Bilgili and Afolabi (2012) also showed that the viscosities of polymer (HPC) 
solutions and milled drug suspensions were higher in the presence of SDS than in its 
absence. This behavior is believed to be caused by the repulsion of adsorbed surfactant 
micelles between polymer chains which increases with the addition of surfactant until the 
polymer chains become saturated. The fact that a similar increase in viscosity with 
increasing surfactant concentration is also present under the viscous conditions required 
for film formation suggests that the same principle could apply to more viscous systems, 




the viscosity of all film precursors was sufficiently high enough so that the differences in 
precursor viscosity between formulations are unlikely to have appreciable influence on 
the RSD values describing the content uniformity of the resulting films.  
2.3.2 Drug Particle Size after Milling and Redispersed from Films 
Nano-milled BCS class II drugs have been shown to exhibit enhanced bioavailability 
owing to the increased specific surface area of the drug particles (Merisko-Liversidge et 
al., 2003), provided that the drug particles retain their small size upon incorporation into 
the final dosage form (Merisko-Liversidge and Liversidge, 2011). The ability of the film 
format to impart physical stability to the milled drug particles was investigated by 
redispersing the particles from the film in water, measuring their sizes, and comparing 
their sizes against those of the milled drug particles (Beck et al., 2013; Sievens-Figueroa 
et al., 2012a; Susarla et al., 2013). If the drug particles redispersed from the film are 
comparable in size to the drug particles in the milled suspension, it may be concluded that 
the embedded drug particles are stabilized within the film. 
Particle size distribution data for drug particles in milled suspension prior to shear 
mixing with polymer solution and for drug particles redispersed from dry films is given 
in Table 2.4. Suspension size data suggests that WSMM allowed for preparation of drug 
nanosuspensions with median sizes < 400 nm (except G1). Despite being subjected to 
identical milling conditions and milling time, FNB, GF, and AZD all yielded suspensions 
with significantly smaller drug particle sizes (> 100 nm difference in median particle 
size) with surfactant than without, particularly GF which exhibited micron-size 
agglomerates in the absence of surfactant. This behavior was expected, as the addition of 




stabilizing effects when used in conjunction with nonionic polymer, generally yielding 
smaller particle sizes (Bhakay et al., 2014a; Bilgili and Afolabi, 2012). In addition, the 
significant fraction of particles between 1-2 µm in the AZD suspensions may be 
attributed to its hardness and higher solubility in water relative to the other drugs used in 
this study (Bhakay et al., 2011; Keck and Müller, 2006). However, the enhanced 
stabilization offered by surfactant for WSMM is not always as pronounced or even 
required, as demonstrated by the similar median particle sizes of the NPX and PB 
suspensions (141/136 nm and 156/176 nm without surfactant/with surfactant, 
respectively). 
Table 2.4 Particle Size Distribution of Drug in Milled Suspension Prior to Shear Mixing 
with Polymer Solution (Susp) and Drug Redispersed from Dry FNB, GF, NPX, PB and 
AZD Films (Film) 
Formulation __F1__ __F2__ __G1__ __G2__ __N1__ 
Source Susp Film Susp Film Susp Film Susp Film Susp Film 
d10 (nm) 160 151   67 135    150 103 123 109   76   75 
d50 (nm) 280 275 178 283 1,460 238 161 164 141 138 
d90 (nm) 503 489 417 620 5,178 491 214 269 246 248 
Formulation __N2__ __P1__ __P2__ __A1__ __A2__ 
Source Susp Film Susp Film Susp Film Susp Film Susp Film 
d10 (nm)   70   68 102      100 113   94    235    229    181    222 
d50 (nm) 136 134 156   5,496 176 184    370    366    278    352 
d90 (nm) 313 359 254 63,004 282 430 1,719 1,744 1,831 1,685 
 
Although the median particle size of the milled suspensions ranged from 130-370 
nm across all formulations (except G1), it will be demonstrated in Sub-section 2.3.3.7 
that particle size variation within this range has no significant impact on the dissolution 
rate of drug from the resulting films. Thus, the primary concern is to ensure that the drug 
nanoparticles do not experience any agglomeration during film production. The size of 




the size of the drug particles in the respective milled suspensions, all with median particle 
sizes below 400 nm (Table 2.4). This suggests that the drug nanoparticles in these films 
did not further agglomerate upon incorporation into films for both SDS and SDS-free 
formulations, demonstrating the ability of the polymer matrix of the film to stabilize these 
drug nanoparticles just as well without the aid of surfactant. This can be traced back to 
the additional polymer added during the preparation of the film precursor suspension, 
leading to a drug:polymer mass ratio of ~1:4 (Table 2.2). This extra polymer helps to 
preserve the drug particle size within the film while also enhancing the stabilization of 
the drug particles upon redispersion via adsorption (Bilgili and Afolabi, 2012; Knieke et 
al., 2013), allowing for recovery of the drug nanoparticles from films in redispersion. 
Redispersion from P1 (formulation without surfactant) yielded agglomerates, whereas 
redispersion from P2 yielded nanoparticles. However, as will be shown later, this had no 
impact on the film dissolution and may suggest that the redispersion protocols employed 
are conservative and may not necessarily assess the extent of reversible agglomeration. In 
other words, the redispersion test and dissolution test have different hydrodynamic 
conditions and they correspond to different measurement times, hence their results are 
expected to have some differences. Redispersion from both GF films yielded 
nanoparticles despite agglomeration in the surfactant-free suspension, implying that the 
GF agglomerates produced in the surfactant-free suspension are breakable upon 
redispersion, allowing for recovery of the primary nanoparticles. Analysis of SEM 






2.3.3 Film Characterization 
2.3.3.1 Drug Content and Uniformity in Films.  As with any pharmaceutical 
dosage form, content uniformity is essential to ensuring product quality. Although the 
capability of forming strip films containing uniformly dispersed GF nanoparticles has 
been demonstrated previously (Davé et al., 2014; Susarla et al., 2013), the same has not 
yet been shown for other BCS class II drugs. The average and relative standard deviation 
(RSD) for film thickness, drug mass per unit area of film and drug loading on a w/w basis 
for all formulations are shown in Table 2.5. It is emphasized that the film samples are 
very small, ~0.71 cm
2
 and thus about 1/10
th
 of the expected dosage size, hence the final 
dosage RSD values are expected to be even lower/better than those reported here. It 
should be noted that some variability in drug mass per unit area is due to variability in 
film thickness, the optimization of which is beyond the scope of this study. This effect 
can be seen by comparing thickness and mass RSDs to that of drug loading (wt%), which 
is significantly less than the other two as a result of being inherently normalized by the 
mass of each sample measured. The variation in drug distribution throughout the films by 
mass per unit area was within 6% RSD, and most are < 3% RSD. Not only does this 
consistency demonstrate the robustness of the film manufacture process to produce films 
with good content uniformity for a wide variety of poorly water-soluble drugs, but it also 
emphasizes the capability of the strip film format as a whole to produce dosages with 
uniform drug content, even for doses as low as 1-2 mg, a significant challenge for other 





Table 2.5 Content Uniformity and Thickness Variation within Films Containing FNB, 
















F1   92.8 2.4% 1.71 2.8% 14.9 2.0% 
F2 102.0 1.4% 2.08 4.2% 17.0 2.6% 
G1   92.9 2.4% 1.95 1.8% 15.2 1.3% 
G2   95.4 2.7% 1.93 3.5% 14.5 1.2% 
N1 101.5 5.4% 1.53 5.0% 12.7 1.6% 
N2 108.3 0.8% 1.84 3.1% 14.2 1.6% 
P1 107.8 2.2% 1.65 6.5% 13.6 3.6% 
P2   93.4 3.8% 1.90 4.4% 15.1 3.7% 
A1   98.8 2.1% 1.97 3.1% 16.6 2.2% 
A2   92.6 1.4% 2.00 2.7% 17.7 0.7% 
 
While surfactant is known to improve the dispersibility of poorly water-soluble 
drugs and the average film precursor suspension with surfactant was 2000 cP more 
viscous than without, the presence of surfactant in the film did not have either significant 
or consistent effect on film content uniformity across all five drugs under investigation. 
NPX and PB films both exhibited 2% RSD less variation in drug distribution with SDS 
than without, while FNB, GF, and AZD films exhibited less significant differences in 
drug distribution RSD between films with and without SDS. While content uniformity 
improved for AZD films with the inclusion of SDS and declined for FNB and GF films 
with SDS, it is difficult to say whether or not a difference of 1% RSD was due to the 
formulation. When averaged together by SDS content, the variation in drug distribution 
of surfactant-free films was 3.8% RSD and thickness variation was 2.9% RSD, 
demonstrating the feasibility of producing uniform films loaded with drug nanoparticles 
without the need for surfactant. When averaged together, films containing surfactant 
exhibited comparable variation in drug distribution, 3.6% RSD and in thickness 2.0% 




in suspension does not influence the content uniformity of films made from those 
suspensions, positively or negatively. 
2.3.3.2 Film Mechanical Properties. In addition to the importance of having 
flexible films with sufficient mechanical strength, the mechanical properties of films may 
also influence dissolution kinetics, as will be discussed in Sub-section 2.3.3.7 
(Mangwandi et al., 2014). The tensile strength (TS), yield strength (YS), Young’s 
modulus (YM), and percent elongation at break (EB) for all film formulations are shown 
in Table 2.6. NPX, PB, and AZD films all exhibited TS around 30 MPa, YS around       
25 MPa, YM around 2.0 GPa, and EB around 23%. GF and FNB exhibited significantly 
higher TS (~47 MPa), YS (~41 MPa), YM (~2.8 GPa), and lower EB (~16%) than the 
other three drugs. As will be shown in Sub-section 2.3.3.4, films containing less water-
soluble drug nanoparticles also retained less water upon drying, which is known to 
contribute to increased tensile strength and decreased elasticity (Biliaderis et al., 1999). 










F1 45.7 ± 2.0 41.8 ± 3.8 2.62 ± 0.19 14.2 ± 5.4 
F2 49.0 ± 3.4 47.0 ± 1.8 3.02 ± 0.14 13.4 ± 2.3 
G1 45.5 ± 2.4 37.0 ± 0.4 2.68 ± 0.17 20.5 ± 2.8 
G2 50.4 ± 4.3 43.4 ± 2.8 2.79 ± 0.13 16.9 ± 2.5 
N1 26.1 ± 3.5 22.0 ± 2.1 1.58 ± 0.17 23.2 ± 3.8 
N2 32.7 ± 0.6 27.2 ± 0.9 1.96 ± 0.08 23.4 ± 2.0 
P1 28.8 ± 0.9 25.4 ± 0.6 1.82 ± 0.07 20.4 ± 1.9 
P2 33.0 ± 2.3 28.2 ± 0.5 2.20 ± 0.06 22.2 ± 1.3 
A1 30.2 ± 0.2 22.4 ± 0.8 2.22 ± 0.10 25.4 ± 0.6 
A2 29.7 ± 0.8 23.3 ± 0.0 2.28 ± 0.07 21.4 ± 2.1 
X1 36.8 ± 0.8 25.3 ± 1.1 1.88 ± 0.08 27.6 ± 1.2 





Interesting outcomes are seen in terms of the impact of the SDS on film 
mechanical strength. Although placebo films exhibited an 11 MPa decrease in TS upon 
addition of SDS, an increase of ~5 MPa in TS was observed upon incorporation of SDS 
in films for all drugs except AZD, for which no significant difference was observed 
between films with and without SDS. While surfactant is known to exhibit a plasticizing 
effect in polymer films (Rodríguez et al., 2006), as is observed in the placebo films, it is 
hypothesized that the dominant role of SDS in the drug-loaded films is that of a 
nanoparticle stabilizer. Since the drug particles are milled along with the SDS and no 
additional SDS is added upon mixture with polymer solution, it follows that most of the 
SDS in the film precursor suspension and subsequent dry film should be adsorbed onto 
the surface of the drug nanoparticles. As a result, the ionic stabilization imparted to the 
drug nanoparticles by the SDS may allow for more favorable interaction with the HPMC, 
strengthening the polymer network. The opposite is true when drug nanoparticles are 
incorporated into films without any form of ionic stabilization, as the exposed 
hydrophobic surfaces may serve to weaken the polymer network. 
2.3.3.3 Scanning Electron Microscopy (SEM). SEM images were taken to 
qualitatively confirm drug nanoparticle size and morphology within the polymer matrix 
of the dry films. Cross-sectional images for each film are shown in Figure 2.1 and surface 
images for select films are shown in Figure 2.2. The drug nanoparticles seem to be well-
dispersed and encapsulated by the polymer owing to ~4:1 polymer-to-drug ratio to such 
an extent that depending on the cut surface, they may not even appear clearly         
(Figure 2.1). While these images may not be representative of the whole film, this 




excess polymer added during the preparation of the film precursor suspension. With the 
exception of GF, no significant nanoparticle agglomeration was observed from the 
acquisition of the cross-sectional images. In agreement with suspension sizing data, G1 
(Figure 2.1c) exhibited some agglomeration of nanoparticles in the film, whereas G2 
(Figure 2.1d) did not, owing to the electrostatic stabilization provided by the surfactant in 
the nanosuspension. The ability to recover GF nanoparticles after redispersion from the 
surfactant-free film is indicative of reversible or soft agglomerates which are not 
expected to impact the dissolution rate as they break apart to reform the original 
nanoparticles under light mechanical forces or hydrodynamic stress. The largest 
observable PB particles in P1 surface images were 1-2 µm in size (Figure 2.2a), well 
below the 5.5 µm median size of the particles redispersed from the film. This suggests 
that the PB particles may have formed irreversible agglomerates of smaller aggregates of 
1-2 µm that could not be completely redispersed from the P1 film as per the redispersion 
protocol. AZD film surface images revealed micron-size drug particles, as well (Figure 
2.2b). Since these micron-size particles were also present in the original AZD 
nanosuspensions and were preserved as such upon incorporation into the film format, the 
presence of micron-size AZD particles in the film is likely a result of the difficulty of 
nano-milling AZD due to its hardness and relatively high solubility in water compared to 
the other drugs under investigation, as opposed to the film manufacture process. These 
findings corroborate the robustness of the film format to stabilize drug nanoparticles 
formed via WSMM with and without surfactant, as the drug particles observed in every 




from which they were taken, with the exception of P1 whose drug particles may not have 




Figure 2.1 Cross-sectional SEM images of films containing (a,b) FNB, (c,d) GF,        










Figure 2.1 (Continued) Cross-sectional SEM images of films containing (a,b) FNB,   




Figure 2.2 SEM surface images of films (a) P1 [PB without SDS], and (b) A2          








2.3.3.4 Thermogravimetric Analysis (TGA). TGA analysis was done and curves 
were normalized to account for varying drug and SDS content between films          
(Figure 2.3). Weight loss up to 100 ºC was between 2-8 wt% for NPX, PB, and AZD 
films, primarily due to the loss of free or bound water. This percentage dropped to 1% for 
FNB and GF films, most likely due to the lower water solubility of the incorporated drug 
nanoparticles. This is in line with the increased mechanical strength and decreased 
elasticity exhibited by FNB and GF films, as films with less bound water are generally 
more brittle (Biliaderis et al., 1999). 15 min exposure to 150 ºC resulted in additional 
weight loss of 10-15 wt% for all films, mainly attributed to the loss of glycerin (Susarla 














































Figure 2.3 Normalized TGA curves for films containing FNB, GF, NPX, PB, and AZD 
nanoparticles (a) without SDS and (b) with SDS. 
 
2.3.3.5 Fourier Transform Infrared (FTIR) Spectroscopy. To observe potential 
molecular interactions between components within the film, FTIR spectroscopy was 
performed on all film samples and pure drug powder (Figure 2.4). All drug-laden film 
samples exhibited a positive peak shift of 5-12 cm
-1
 for the C–O–C stretch and/or C–O 
(R–CH2–OH) stretch in HPMC from their respective 1113 cm
-1
 and 1054 cm
-1




the drug-free placebo films, indicative of polymer–drug interaction. In addition, NPX and 
AZD spectra also revealed a shift in hydrogen bonding from drug–drug to polymer–drug 
within the film. The COOH dimer peak at 1684 cm
-1
 for NPX, indicative of drug–drug 
hydrogen bonding, disappears entirely from the film spectra while the COO
‒
 peak at  
1396 cm
-1
 splits to form a doublet peak with 1375 cm
-1
 (Figure 2.4c). Disappearance of 
the NPX dimer peak due to interaction with the polymer matrix was also observed in 
polyvinylpyrrolidone films by Nair et al. (2001). The C═O stretch peak for AZD at   
1724 cm
-1
 splits to form a doublet peak with 1740 cm
-1
 in the film spectra (Figure 2.4e). 
In addition, the two peaks associated with the combination of NH2 scissoring and C═O 
stretching for AZD at 1662 cm
-1
 and 1638 cm
-1
 shift to 1677 cm
-1
 and disappear entirely 
from the film spectra, respectively, suggesting preferred hydrogen bonding with the 
polymer than with other AZD molecules (Lee et al., 2008). This preferred hydrogen 
bonding between drug molecules and polymer suggests that the additional polymer 
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Figure 2.4 FTIR spectra of pure drug and films containing (a) FNB, (b) GF, (c) NPX,  





2.3.3.6 Raman Spectroscopy. Raman spectroscopy was employed to investigate 
the crystallinity of the drug within the films. Raman spectra for pure amorphous drug, as-
received pure crystalline drug powder, drug-loaded film without SDS, drug-loaded film 
with SDS, and placebo film are shown in Figure 2.5. Although some films exhibited 
stronger drug peaks than others, characteristic peaks for all drugs were evident in their 
respective film spectra. 
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Figure 2.5 Raman spectra of pure drug and films containing (a) FNB, (b) GF, (c) NPX, 
(d) PB, and (e) AZD nanoparticles. 
 
The most prominent peaks displayed in the FNB film spectra were at 1148, 1602, 
and 1652 cm
-1
 for C–O stretching, in-plane benzene ring stretching and C═O stretching, 
respectively (Heinz et al., 2009), which overlapped with the corresponding peaks of the 
pure drug powder spectrum (Figure 2.5a). FNB films also displayed a peak at 124 cm
-1
 
which overlapped with the 124 cm
-1
 peak of the pure drug powder spectrum not present 
in the amorphous spectrum (any peaks at 104 cm
-1




spectrum, are likely artifacts caused by notch filter cutoff). GF films and pure GF powder 
shared a trio of peaks between 1600 and 1750 cm
-1
 corresponding to C═O stretching of 
the benzofuran ring (Figure 2.5b). Although the GF signal from the GF films was 
relatively weak, all three peaks in this trio exhibited a noticeable shift from the crystalline 
form to the amorphous form and the peaks visible in the film spectra aligned with those 
of the crystalline drug. The strongest peak present in the NPX film spectra occurred at 
1394 cm
-1
 corresponding to the in-plane bend for the naphthalene ring of NPX, also 
present in the spectrum for pure crystalline NPX and clearly absent from the placebo film 
spectrum (Figure 2.5c). However, Raman was unable to distinguish between the 
crystalline and amorphous forms of NPX. PB film spectra exhibited peaks at 1002 for   
C–H wagging and 1596 cm
-1
 for aromatic C═C stretching also seen in the pure drug 
spectrum (Figure 2.5d). PB films also exhibited a matching peak at 130 cm
-1
 with the 
crystalline spectrum absent from the amorphous spectrum. Peaks at 1122, 1340, and  
1576 cm
-1
, corresponding to the NH2 rock + C═O stretch + C‒N stretch, C‒N stretch + 
N‒C═O bend + NH2 rock, and N═N stretch in AZD, respectively, can clearly be seen in 
both AZD film spectra and the crystalline AZD spectrum, but not in the amorphous 
spectrum (Figure 2.5e) (Lee et al., 2008; Xie et al., 2013). 
Alignment of the drug spectral peaks for both drug-loaded films with those of 
their respective crystalline drug spectra as opposed to those of the amorphous drug 
spectra demonstrates that the crystallinity of the drug was maintained throughout the film 
manufacture process for all drugs under investigation. 
2.3.3.7 Dissolution.  A comparison between the dissolution profiles of films 




Figure 2.6. NPX and AZD exhibited statistically similar dissolution profiles with and 
without SDS according to similarity and difference factors (Boateng et al., 2012; Costa 
and Lobo, 2001), indicating that the presence of surfactant in the film had little influence 
on the rate of drug release from films containing these two drugs. Interestingly, FNB, GF, 
and PB films all exhibited a statistically significant decrease in dissolution rate with the 
incorporation of SDS than without. This finding was surprising as surfactants generally 
enhance the rate of release of poorly water-soluble drugs (Bhakay et al., 2014a; Bhakay 
et al., 2014b). The slower dissolution may be attributed to the greater mechanical strength 
exhibited by the films containing surfactant. It is more evident when the dissolution 
profiles are grouped by surfactant content in Figure 2.7, shown for the sake of easier 
comparison. These results are in line with previous work, which has shown that changes 
in film formulation, such as film-forming polymer MW (Prodduturi et al., 2005), that 
result in changes in film mechanical properties may also influence the dissolution rate of 
the film. Specifically, slower dissolution was observed from films with increasingly 
greater tensile strength. Likewise, Mangwandi et al. (2014) observed a similar correlation 





































































































Figure 2.6 Comparison of release profiles from films containing (a) FNB, (b) GF,         





















































Figure 2.7 Comparison of drug release profiles in SDS media from films containing 
FNB, GF, NPX, PB, and AZD nanoparticles (a) without SDS and (b) with SDS. 
 
It is hypothesized that, due to the high polymer concentration necessary for film 
formation, drug release is limited by erosion of the polymer matrix, effectively masking 
any potential effects of drug properties or surfactant on dissolution rate. As such, it 
follows that any significant difference in the mechanical properties between films in a 
polymer matrix erosion-limited system would be manifested in differences between their 
dissolution profiles. That said, the complex nature of nanoparticle release from polymer 
films must also be acknowledged. While every effort was made to ensure the following 




etc. may also play a role in determining drug dissolution rate, making it difficult to 
pinpoint a single source of variation between dissolution profiles. Nonetheless, most 
films achieved 80% drug dissolution (t80) between 18-28 min in spite of these potential 
variations as well as the differences in drug solubility and surfactant content between 
formulations, suggesting that the film format offers reliable and controlled solubilization 
of the embedded drug nanoparticles. 
To further elucidate the potential impact of surfactant on dissolution, similar tests 
were performed in DI water media for NPX, PB, and AZD films. Such tests were not 
performed for FNB or GF, as their water solubilities, 0.7 and 8.6 µg/ml, respectively, 
were too low to make such a test practical for those drugs. As shown in Figure 2.8, 
despite being released into a surfactant-free medium, PB and AZD films exhibited 
statistically similar dissolution profiles with and without SDS, further emphasizing that 
surfactant is unnecessary to achieve enhanced dissolution of drug nanoparticles from 
films. The slight difference between NPX films may be attributed to the greater 
mechanical strength of N2 compared to N1, leading to slower dissolution in DI water. 
This consistency in dissolution demonstrates the robustness of the film format to release a 
wide variety of poorly water-soluble drug nanoparticles within a similar timeframe, even 

































































Figure 2.8 Comparison of release profiles from films containing (a) NPX, (b) PB, and  
(c) AZD nanoparticles in DI water media. 
 
 Conclusions 2.4
The ability of the polymer strip film format to effectively stabilize and deliver a variety 
of BCS class II drug nanoparticles with and without the aid of surfactant was 
investigated. In general, drug nanoparticles were successfully recovered upon 
redispersion from FNB, GF, NPX, and AZD films with and without SDS, suggesting 
surfactant is not required to recover nanoparticles of these drugs from the polymer film. 
Films exhibited very good content uniformity in terms of drug distribution and thickness 




high quality films can be made incorporating a variety of BCS class II drugs. The 
presence or absence of SDS was found to have little impact on the content uniformity of 
the films overall, suggesting that surfactant is unnecessary to produce films with good 
content uniformity.  
Overall, all films exhibited fast dissolution from all five drugs. Specifically, most 
films achieved 80% dissolution between 18 and 28 min with similar dissolution profiles 
in both SDS and DI water media irrespective of the drug or surfactant content in the film. 
This consistency in fast dissolution across a wide solubility range of poorly water-soluble 
drugs further reinforces the robustness of polymer strip film platform for the delivery of 
poorly water-soluble drugs while the same consistency between formulations with and 
without surfactant demonstrates the capability of polymer strip films as a surfactant-free 
format without sacrificing enhanced dissolution rate or drug content uniformity.  
The need for relatively high polymer concentrations in film formulations is a 
unique and important feature of the film format for its use in bioavailability enhancement 
of BCS class II drug nanoparticles in contrast to other solid dosages incorporating core-
shell or spray-died nanocomposite powders. Additional excess polymer is required to 
achieve a high film precursor suspension viscosity (~8,000 cP), which led to wrinkle-
free, flexible films with excellent content uniformity, effective encapsulation of the drug 
nanoparticles in the film which helps to preserve the drug nanoparticle size upon 
redispersion of the films in water, and most importantly, fast drug release. All of this was 
possible without the need for surfactants, which is a unique and novel aspect of the strip 






3 EFFECT OF PLASTICIZER___ 
 
 Introduction 3.1
Generally speaking, plasticizers are additives that increase the plasticity or fluidity of a 
material. In strip films, this is typically achieved by introducing a plasticizer in the form 
of a relatively small molecule that is miscible with the film-forming polymer, allowing 
for molecular-level interaction between the plasticizer and polymer to moderate polymer–
polymer interaction, thereby promoting mobility of the polymer chains (Bruce and 
McGinity, 2008). This is manifested in a depression of the glass transition temperature, as 
well as decreased tensile strength and increased elongation in the resulting films 
(Wypych, 2004). This phenomenon has been reported for a multitude of polymer–
plasticizer combinations, but such studies have mainly been limited to drug-free films 
(Aulton et al., 1981; Bodmeier and Paeratakul, 1994; Entwistle and Rowe, 1979; 
Gutiérrez-Rocca and McGinity, 1994; Honary and Orafai, 2002; Hutchings et al., 1994; 
Hyppölä et al., 1996; Lim and Hoag, 2013; Lourdin et al., 1997; McHugh and Krochta, 
1994; Sakellariou et al., 1986; Thakhiew et al., 2010). Plasticizers are particularly useful 
in pharmaceutical films, as most film-forming polymers produce hard or brittle films in 
the absence of plasticizer, resulting in handling/packaging difficulties and poor patient 
compliance. This has led to investigations of the impact of plasticizer on various 
properties of polymer films loaded with water-soluble drug (Gottnek et al., 2013; 
Pongjanyakul and Puttipipatkhachorn, 2007) and amorphous poorly water-soluble drug 




poorly water-soluble drug particles, let alone the effect of plasticizer or plasticizer 
content on drug release from such films. 
While most literature and commercial applications involving polymer films for 
drug delivery have focused on orodispersible films for water-soluble drugs (Borges et al., 
2015a; Dave et al., 2014; Dixit and Puthli, 2009; Garsuch and Breitkreutz, 2010), the 
potential for successful delivery of poorly water-soluble drugs via strip films had gone 
untapped until recently. Use of poorly water-soluble drugs introduces two additional 
challenges to drug delivery: overcoming limited solubility to improve bioavailability 
(Kesisoglou et al., 2007) and ensuring that the enhanced bioavailability is preserved upon 
delivery (de Villiers, 1996; Krull et al., 2015a). The two most commonly used methods to 
overcome these challenges, organic solvent casting (Kumar et al., 2014; Visser et al., 
2015) and hot melt extrusion (Prodduturi et al., 2005), both pose inherent limits to drug 
loading in the film and may lead to instability of the embedded drug (Kipp, 2004). 
Several particle engineering techniques have demonstrated promise in terms of producing 
stable poorly water-soluble drug particles for incorporation into and fast dissolution from 
polymer strip films with less stringent limitations on drug loading, including production 
of drug nanoparticles via wet stirred media milling (WSMM) (Krull et al., 2016b; 
Sievens-Figueroa et al., 2012a; Susarla et al., 2015; Susarla et al., 2013), high pressure 
homogenization (Lai et al., 2015; Shen et al., 2013), liquid antisolvent precipitation 
(Beck et al., 2013), and melt emulsification (Bhakay et al., 2016). However, none of 





This chapter demonstrates that the mechanical properties of polymer strip films 
loaded with poorly water-soluble drug can be manipulated within a desirable range 
without sacrificing fast dissolution or nanoparticle redispersibility of the embedded 
poorly water-soluble drug. 
 
 Experimental Procedures 3.2
Experimental procedures for the preparation of polymer films containing GF 
nanoparticles, film mechanical properties, TGA, and SEM are identical to their respective 
procedures described in Sub-section 2.2. 
3.2.1 Materials 
Griseofulvin (GF; Letco Medical, Decatur, AL, USA) was selected as a model BCS class 
II drug. Hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV, The Dow 
Chemical Company, Midland, MI, USA) served as the film-forming polymer. HPMC-
E15LV also served as a nanoparticle stabilizer in suspension, along with the surfactant 
sodium dodecyl sulfate (SDS; Fisher Scientific, Pittsburgh, PA, USA). Glycerin (Sigma–
Aldrich, St. Louis, MO, USA), triacetin (Sigma–Aldrich, St. Louis, MO, USA), and 
polyethylene glycol (PEG-400; Sigma–Aldrich, St. Louis, MO, USA) were selected as 
film plasticizers for their miscibility with HPMC and limited volatility. Particle size 
reduction of GF was performed by WSMM according to Sub-section 3.2.2.1. All other 
materials were used without further processing. 
3.2.2 Preparation Methods 
3.2.2.1 Preparation of GF Nanosuspension. GF nanosuspension was prepared via 




USA). Methods and stabilizer concentrations were selected according to previous 
optimization studies (Bilgili and Afolabi, 2012; Monteiro et al., 2013). The suspension 
consisted of 10% GF (w/w wrt water) dispersed in a stabilizer solution of                   
2.5% HPMC-E15LV and 0.5% SDS (both w/w wrt water), and was milled for 120 min. 
3.2.2.2 Preparation of Film Precursor Suspensions. Formulations for film-
forming polymer solutions are listed in Table 3.1. As per Dow
®
 protocol, polymer 
solutions were prepared by adding the appropriate amounts of HPMC-E15LV and 
plasticizer (as necessary) to water at 90 ºC, after which the solution was allowed to cool 
to room temperature under continuous magnetic stirring. Polymer concentrations were 
selected such that the polymer solutions were sufficiently viscous to ensure a uniform 
film (Susarla et al., 2013) while not too viscous to hinder mixing or casting. Polymer 
solutions consisted of 15 wt% HPMC with different plasticizers (glycerin, triacetin, and 
PEG-400) and plasticizer content (0.0, 2.5, and 5.0 wt%). Plasticizer concentrations were 
kept at or below 5.0 wt% in order to avoid over-plasticization of the films, which can 
result in oily films that are difficult to handle. Each of the resulting polymer solutions 
was mixed with GF nanosuspension in a 2:1 ratio by mass using a Thinky ARE-310 
planetary centrifugal mixer (Thinky, Laguna Hills, CA, USA). Polymer solution and 
nanosuspension were mixed at 2000 rpm for 30 s, followed by 7 min of deaeration at 
2200 rpm, to form film precursor suspension. If bubbles were still present in the 






Table 3.1 Film-Forming Polymer Solution Formulations Prior to Mixing with GF 
Nanosuspension 
Formulation Plasticizer wt% HPMC wt% plasticizer wt% water 
0.0% Plasticizer N/A 15.0 0.0 85.0 
2.5% Glycerin Glycerin 15.0 2.5 82.5 
5.0% Glycerin Glycerin 15.0 5.0 80.0 
2.5% Triacetin Triacetin 15.0 2.5 82.5 
5.0% Triacetin Triacetin 15.0 5.0 80.0 
2.5% PEG PEG 15.0 2.5 82.5 
5.0% PEG PEG 15.0 5.0 80.0 
 
3.2.3 Characterization Methods 
3.2.3.1 Viscosity of Polymer Solutions and Film Precursor Suspensions. The 
apparent shear viscosity of polymer solutions and film precursor suspensions was 
measured with an R/S-CC+ Coaxial Cylinder Rheometer (Brookfield Engineering, 
Middleboro, MA, USA) equipped with a shear rate controlled coaxial cylinder (CC25) 
and Lauda Eco water jacket assembly (Lauda-Brinkmann LP, Delran, NJ, USA) for 
temperature control. Both were subjected to a low shear rate program (0-20 s
-1
) at          
25 ± 0.5 ºC to measure low shear viscosity. Raw data was analyzed using Rheo 3000 
software (Brookfield Engineering, Middleboro MA, USA). Experiments were performed 
a minimum of seven times. 
3.2.3.2 GF Particle Size after Milling and Redispersed from Films. GF particle 
size distributions were measured both in suspension immediately after milling and 
following redispersion from films utilizing a Coulter LS 13320 Laser Diffraction Particle 
Size Analyzer (Beckman Coulter, Miami, FL, USA) employing a polarized intensity 
differential scattering (PIDS) obscuration water optical model. The PIDS was maintained 




used to calculate particle size distributions. Suspension samples for particle size after 
milling were prepared by removing a 1.2 ml sample from the holding tank of the mill, 
dispersing the sample into 4 ml of stabilizer solution (2.5% HPMC-E15LV and         
0.5% SDS, both w/w wrt water) via pipette, and vortex mixing for 1 min at 1500 rpm. 
In order to evaluate the ability to recover GF nanoparticles from films upon 
delivery, redispersion samples to determine GF particle size after incorporation into dry 
films were prepared by dispersing three circular film punches ~0.7 cm
2
 in area into 3 ml 
of deionized water, followed by 3-5 min of vortex mixing at 1500 rpm. These samples 
were then subjected to the same particle size analysis as the milled suspension samples. 
3.2.3.3 Differential Scanning Calorimetry (DSC). A Polymer DSC (Mettler 
Toledo, Columbus, OH, USA) was used for differential scanning calorimetry. 5-6 mg 
samples were placed in sealed aluminum pans, initially cooled to -50 ºC at a rate of          
-10 ºC/min, heated to 250 ºC at 10 ºC/min, cooled to -50 ºC at -10 ºC/min, and again 
heated to 250 ºC at 10 ºC/min, all under nitrogen flow. 
3.2.3.4 Determination of Drug Content and Uniformity in Films. Ten circular 
samples ~0.7 cm
2
 in area were removed from random points throughout each film and 
dissolved in 250 ml of 5.4 mg/ml SDS solution under continuous stirring for a minimum 
of 3 h. Despite being roughly 1/10
th
 the size of a traditional film dosage, this smaller size 
was used to help elucidate differences in uniformity between film formulations. The UV 
absorbance of each sample at the wavelength of maximum absorbance for GF (291 nm) 
was then measured using a Thermo Scientific Evolution 300 UV-Vis spectrophotometer 
(Thermo Fisher Scientific Inc., MA, USA). The concentrations of the respective samples 




GF weight per unit area of film and average weight percentage of GF in the film over ten 
samples. 
3.2.3.5 Flow-through Cell Dissolution (USP IV).  Dissolution experiments were 
performed using a flow-through cell dissolution apparatus (USP IV; Sotax, Switzerland) 
with cells of 22.6 mm internal diameter and 0.2 µm Pall HT Tuffryn filters. Dissolution 
samples were automatically measured in-line every two minutes by the same Thermo 
Scientific Evolution 300 UV-Vis spectrophotometer (Thermo Fisher Scientific Inc., MA, 
USA) used for determination of drug content and uniformity in films (Sub-section 
3.2.3.4). One circular film sample ~0.7 cm
2
 in area was horizontally secured within 5 g of 
1 mm glass beads at the bottom of each cell (3 g below the film and 2 g above). 100 ml of      
5.4 mg/ml SDS solution (recommended for GF by the United States Pharmacopeia) was 
circulated through each cell at a flow rate of 16 ml/min and a constant temperature of    
37 ± 0.5 ºC. These dissolution protocols were selected for their discriminatory power 
demonstrated in previous work between films containing nanoparticles, films containing 
microparticles, and compacted powders (Beck et al., 2013; Bhakay et al., 2016; Sievens-
Figueroa et al., 2012b). Dissolution results are reported as GF release as a function of 
time for an average of six samples from each film. Percentage GF released was calculated 
based on the expected drug loading in each sample from the drug content assessment 
performed for each film formulation (Sub-section 3.2.3.4), taking into consideration the 
weight of each individual film sample. 
3.2.3.6 Long-Term Stability of Films. Films designated for long-term stability 
study were stored in a MicroClimate benchtop climate chamber (Cincinnati Sub-Zero, 




6 months of storage under these conditions, films were subjected to redispersion and 
dissolution tests as outlined in Sub-sections 3.2.3.2 and 3.2.3.5, respectively. 
3.2.3.7 Statistical Analysis. All calculations were performed using Microsoft 
Excel
®
 (Microsoft Office 2010, USA). Results for viscosity, mechanical properties, and 
dissolution profiles are expressed as mean ± SD (standard deviation) while content 
uniformity results are expressed as mean with RSD % (relative standard deviation). 
Dissolution profiles were compared using similarity and difference factors (Boateng et 
al., 2012; Costa and Lobo, 2001). 
 
 Results and Discussion 3.3
3.3.1 Viscosity of Polymer Solutions and Precursor Suspensions 
Low shear (2.2 s
-1
) viscosity measurements for polymer solutions and film precursor 
suspensions, performed with the objective of mimicking conditions of film casting, are 
presented in Figure 3.1. The viscosities of the polymer solutions ranged from           
9,500-14,000 cP. Upon dilution with aqueous GF nanosuspension that contained about 
88.5 wt% water, the viscosities of the film precursor suspensions ranged from          
5,000-7,000 cP. Polymer solutions with 5.0% plasticizer exhibited greater viscosities than 
those with 2.5% plasticizer for all three plasticizers, which may be explained by the fact 
that the added plasticizers were of greater viscosity (1,400 cP for glycerin, 23 cP for 
triacetin, and 60 cP for PEG-400) than the water they displaced from the formulation 
(Table 3.1). These trends were also observed in the film precursor suspensions, although 
not as prominently due to dilution with GF nanosuspension. However, there was a clear 




the plasticizer-free polymer solution. This may be the result of easier slippage of polymer 
chains under shearing due to the initial incorporation of plasticizer, which effectively 


























































Figure 3.1 Low shear (2.2 s
-1
) room temperature viscosity of polymer solutions and film 
precursor suspensions. Values are mean ± SD, n = 7. 
 
3.3.2 GF Particle Size after Milling and Redispersed from Films 
Since the purpose of nanomilling poorly water-soluble drug particles is to enhance their 
dissolution rate and bioavailability, it is crucial that the drug nanoparticles embedded in 
the polymer matrix do not aggregate prior to or upon delivery. Redispersion testing 
provides a means by which the size of the poorly water-soluble drug particles released 
upon delivery can be assessed. As has been shown previously for solid dosage forms 




2013; Krull et al., 2016b), redispersion offers predictive insight into dissolution, as drug 
nanoparticle aggregation or growth can lead to slower drug release. In order to investigate 
the effect of different plasticizers on the ability of the film format to physically stabilize 
the GF particles, redispersion tests were performed on all films on the day of preparation, 
as well as after 3 and 6 months of storage under stress conditions (40 ºC, 75% RH) to 
assess long-term stability (stability results discussed in Sub-section 3.3.3.7). Particle size 
statistics for the milled GF nanosuspension and GF particles redispersed from films in 
deionized water after 0, 3, and 6 months of storage are given in Table 3.2 as 10%, 50% 





Table 3.2 Particle Size Distributions of Fresh GF Nanosuspension and Redispersed Film 
Samples Immediately after Film Preparation, after 3 Months of Storage at 40 ºC,        
75% RH, and after 6 Months of Storage at 40 ºC, 75% RH 
  d10 (µm)  
Formulation Fresh 3 months 6 months 
Suspension 0.099 -- -- 
0.0% Plasticizer 0.104 0.095 0.115 
2.5% Glycerin 0.089 0.098 0.114 
5.0% Glycerin 0.092 0.091 0.113 
2.5% Triacetin 0.106 0.100 0.114 
5.0% Triacetin 0.173 0.064 0.180 
2.5% PEG 0.073 0.069 0.113 
5.0% PEG 0.093 0.094 0.061 
  d50 (µm)  
Formulation Fresh 3 months 6 months 
Suspension 0.159 -- -- 
0.0% Plasticizer 0.231 0.172 0.179 
2.5% Glycerin 0.170 0.171 0.185 
5.0% Glycerin 0.166 0.166 0.190 
2.5% Triacetin 0.241 0.228 0.237 
5.0% Triacetin 0.321 0.250 0.301 
2.5% PEG 0.169 0.161 0.191 
5.0% PEG 0.171 0.212 0.169 
  d90 (µm)  
Formulation Fresh 3 months 6 months 
Suspension 0.262 -- -- 
0.0% Plasticizer 0.509 0.309 0.296 
2.5% Glycerin 0.317 0.301 0.310 
5.0% Glycerin 0.305 0.306 0.328 
2.5% Triacetin 0.422 0.404 0.410 
5.0% Triacetin 0.556 0.476 0.518 
2.5% PEG 0.345 0.343 0.334 
5.0% PEG 0.318 0.390 0.364 
 
GF particle redispersion from fresh glycerin and PEG-400 films yielded d10 
values less than that of the milled suspension and d50 values between 160-170 nm, on par 
with that of the milled suspension, both indicating very good physical stability in the 




262 nm in the suspension, such differences were expected, as the d90 is significantly more 
sensitive to aggregation. On the other hand, slightly larger nanoparticles were redispersed 
from fresh triacetin films (d50 of 241 nm and 321 nm for 2.5% and 5.0% triacetin, 
respectively) and the plasticizer-free film (d50 of 231 nm) compared to those from 
glycerin and PEG-400 films (d50 between 160-170 nm), which increased in size with 
increasing triacetin content. That said, even in the 5.0% PEG film, the d90 value was only 
556 nm, and 100% of all particles were < 1 µm in size (full size distribution not shown). 
As such, these differences in nanoparticle size are not expected to negatively affect drug 
dissolution rate from films under sink conditions (Krull et al., 2016b; Murdande et al., 
2015). 
3.3.3 Film Characterization 
3.3.3.1 Differential Scanning Calorimetry (DSC). One of the defining features 
of a plasticizer is its ability to depress the glass transition temperature (Tg) of a polymer 
due to their molecular-level interaction (Bruce and McGinity, 2008; Wypych, 2004). To 
this end, DSC was employed to observe the influence of plasticizer and plasticizer 
concentration on the Tg of HPMC films loaded with poorly water-soluble drug 
nanoparticles. However, the DSC signal in HPMC films is very weak (Gómez-Carracedo 
et al., 2003; Kararli et al., 1990), often making it difficult to observe the glass transition. 
As such, the first heating cycle was used to determine the Tg for each film. 
The impact of plasticizer and plasticizer concentration on the Tg of GF 
nanoparticle-laden films can be seen in Figure 3.2. These Tg values are in line with those 
observed in literature, which range between 150-200 ºC depending on the grade of 




1999; Nyamweya and Hoag, 2000). Increasing concentration of all three plasticizers led 
to a clear reduction in Tg, a trend which has been observed for multiple polymer–
plasticizer combinations (Hyppölä et al., 1996; Lin et al., 2000; Ljungberg and Wesslén, 
2002, 2003; Pillin et al., 2006; Qussi and Suess, 2006). In spite of the presence of GF 
nanoparticles (15-20 wt%, Sub-section 3.2.3.4), addition of plasticizer shows a clear 
impact on the Tg of the films. This suggests that poorly water-soluble drug nanoparticles 
can be incorporated into polymer films without interfering with the ability of plasticizers 
to interact with the film-forming polymer. PEG-400 led to the greatest depression of Tg 


















































Figure 3.2 (a) Tg and (b) full DSC traces of GF nanoparticle-laden HPMC films 
containing various amounts of plasticizer. 
 
3.3.3.2 Film Mechanical Properties. The role of plasticizers in influencing the 
mechanical properties of drug-free polymer films has been thoroughly investigated in 




1979; Gutiérrez-Rocca and McGinity, 1994; Hutchings et al., 1994; Hyppölä et al., 1996; 
Lim and Hoag, 2013; McHugh and Krochta, 1994). The same has also been investigated 
for drug-loaded films produced via hot melt extrusion (Repka et al., 1999; Zhu et al., 
2006) and solvent casting (Kianfar et al., 2011; Pongjanyakul and Puttipipatkhachorn, 
2007). The consensus is that addition of plasticizer to a polymer film formulation leads to 
a decrease in film strength and an increase in elasticity. However, it is unknown to what 
extent the influence of plasticizers applies to strip films loaded with poorly water-soluble 
drug nanoparticles in terms of film mechanical properties. 
Figure 3.3 depicts the influence of glycerin, triacetin, and PEG-400 on the 
mechanical properties of HPMC films loaded with GF nanoparticles. Films with 
increasing plasticizer content all exhibited decreases in TS, YS, and YM, regardless of 
which plasticizer was used, suggesting that HPMC films containing poorly water-soluble 
drug nanoparticles can be effectively plasticized with a variety of plasticizers. Likewise, a 
general increasing trend in EB was observed with increasing plasticizer content in 
glycerin and PEG-400 films, although there was no such increase in EB for triacetin 
films, which has been previously reported in ethylcellulose films (Hyppölä et al., 1996). 
The order of extent of plasticization according to YS and YM was PEG > glycerin > 
triacetin, which was in line with the trend in Tg depression observed via DSC (Sub-
section 3.3.3.1). This further supports that the presence of poorly water-soluble drug 
nanoparticles does not interfere with the ability of plasticizers to predictably influence 
polymer film mechanical properties. The general similarity between trends exhibited in 




PEG-400 implies that all three plasticizers were similarly effective for HPMC films with 


































































































Figure 3.3 (a) Tensile strength, (b) yield strength, (c) Young’s modulus, and (d) percent 
elongation at break of HPMC films with different plasticizers and content containing GF 
nanoparticles. Values are mean ± SD, n = 4. 
 
3.3.3.3 GF Content and Uniformity in Films. Consistency of drug dosage is 
critical in any pharmaceutical process. In order to assess the drug content of each film 
sample and ensure even distribution of drug throughout each film, content uniformity 
tests were performed for all film formulations. As seen in Table 3.3, all films exhibited 
6% RSD or less in terms of film thickness and GF mass variation, despite the fact that the 
size of each sample was roughly one tenth the size of a typical film dosage (while smaller 
sample sizes were selected to provide better discrimination between formulations in 






would be roughly 1.0-1.5%; results not shown). In addition, triacetin, PEG-400, and 
plasticizer-free films exhibited 2% RSD or less in terms of wt% GF, while glycerin films 
had 4% RSD or less. These results suggest that uniform films with embedded drug 
nanoparticles can be produced with a variety of plasticizers and plasticizer concentrations 
within the range studied. Film thickness generally increased with increasing plasticizer 
content due to the fact that addition of plasticizer displaced water from the film precursor 
formulation (Table 3.1), resulting in less moisture loss, and consequently less thickness 
reduction during the drying process. The same reasoning applies to the decreasing trend 
in wt% GF in films with greater plasticizer content, since the residual mass after drying 
increased with increasing plasticizer content due to less moisture loss. 
Table 3.3 Content Uniformity of HPMC Films with Different Plasticizers and Content. 
Values are an Average of 10 samples ~0.7 cm
2
















0.0% Plasticizer   86.9 3.9% 2.48 4.2% 20.9 2.3% 
2.5% Glycerin   97.1 4.8% 2.57 5.8% 18.2 3.5% 
5.0% Glycerin 108.0 2.9% 2.16 5.5% 15.3 4.2% 
2.5% Triacetin   84.4 4.4% 2.05 5.4% 18.7 1.0% 
5.0% Triacetin   86.6 6.5% 1.99 5.9% 16.4 2.3% 
2.5% PEG   72.2 2.5% 1.68 1.9% 16.6 2.2% 
5.0% PEG   91.1 3.4% 1.99 3.2% 15.4 2.2% 
 
3.3.3.4 Dissolution.  Dissolution curves for all seven fresh films are presented in 
Figure 3.4. By visual inspection of the dissolution curves, it is clear that, with the 
exception of variation in maximum percentage of GF released, there is little difference in 
dissolution rate between the seven film formulations despite their differences in 




pairwise comparison of the dissolution curves using similarity and difference factors 
(Boateng et al., 2012; Costa and Lobo, 2001), according to which the only two films that 
exhibited statistically significant differences in dissolution rate relative to the other five 
formulations were 2.5% triacetin and 2.5% PEG (Appendix A.1). This result 
demonstrates that the mechanical properties of polymer films loaded with poorly water-
soluble drug nanoparticles can be successfully manipulated by multiple plasticizers with 
no significant impact on the rate of drug release from the film. 
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Figure 3.4 Comparison of dissolution profiles between HPMC films loaded with GF 
nanoparticles containing different plasticizers and plasticizer content. Values are       
mean ± SD, n = 6. 
 
While investigation of the impact of various CMAs on dissolution of poorly 
water-soluble drugs from polymer films is ongoing, previous work suggests that, with 
adequate dispersion and stabilization of drug nanoparticles within the film, the major 
controlling factor in determining drug release rate is the polymer matrix. Regarding 




nanoparticles as opposed to microparticles from HPMC films under the same dissolution 
conditions used in this study, while Krull et al. (2016b) observed the same from pullulan 
films in deionized water. Both of these studies reiterate the criticality of preserving 
poorly water-soluble drug particle size in order to maintain enhanced bioavailability upon 
delivery. Since GF particle size was maintained for all seven formulations in this study 
(Section 3.3.2), this was not expected to be a source of difference in film dissolution rate. 
Given proper control of drug particle size, others have demonstrated the impact of other 
CMAs on poorly water-soluble drug dissolution from films, such as added disintegrants 
(Susarla et al., 2015) and the drug itself in Chapter 2, due to their influence on polymer 
erosion (additional CMAs, including film-forming polymer molecular weight (MW) and 
drug loading, will be the subjects of future work). However, given the hydrophilic and 
swellable nature of HPMC, the type and amount of plasticizer added did not appear to 
have a significant influence on the erosion rate of HPMC, resulting in similar dissolution 
profiles for all films. 
While one might have anticipated a direct connection between film mechanical 
strength and dissolution, this relationship is not a simple one. On the one hand, previous 
work has shown that films with greater mechanical strength may exhibit slower drug 
release. Prodduturi et al. (2005) observed slower dissolution for films with greater 
mechanical strength when varying film-forming polymer MW for hot-melt extruded 
poly(ethylene oxide) films containing clotrimazole. A similar correlation was found in 
Chapter 2 where incorporation of different drug nanoparticles into HPMC films led to 
films of varying mechanical strength, which coincided with their respective differences in 




film mechanical strength does not necessarily affect drug release. Pongjanyakul and 
Puttipipatkhachorn (2007) observed similar drug permeation rates between 
acetaminophen tablets coated by sodium-alginate-magnesium aluminum silicate films 
with varying amounts of glycerin and PEG-400, despite significant differences in the 
mechanical properties of the film coatings. Lin et al. (1995) noted little difference in 
permeation profiles of piroxicam from Eudragit E films with varying mechanical 
properties due to incorporation of four different plasticizers. Krull et al. (2016b) observed 
similar dissolution rates from GF nanoparticle-laden films of various drug loadings 
despite significant differences in their mechanical properties. Nonetheless, plasticizer has 
been shown to be a unique tuning parameter for film mechanical properties that does not 
appear to impact drug release, unlike film-forming polymer properties, such as MW, 
which have been shown to affect both. These results suggest that the relationship between 
film mechanical properties and dissolution is more complex than it first appears, and 
further investigation is required to elucidate a possible connection. 
3.3.3.5 Thermogravimetric Analysis (TGA). TGA was performed on all film 
formulations and normalized to account for slight variations in GF and SDS content 
between films according to Susarla et al. (2013) (Figure 3.5). All films exhibited a weight 
loss between 1.5% and 4.5% up to 100 ºC, which can be attributed to the loss of water 
within the film. 15 min exposure to 150 ºC resulted in varying degrees of wt% drops 
between films depending on which and how much plasticizer each film contained, 
suggesting that this drop, or lack thereof, was due to the presence or absence of 
plasticizer in the film formulation. Consequently, the plasticizer-free film exhibited a 




the three plasticizers was glycerin > triacetin > PEG-400, and films with higher 
plasticizer concentration experienced greater drops in wt% due to the loss of additional 
plasticizer. 
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Figure 3.5 Normalized TGA curves for HPMC films with different plasticizers and 
plasticizer content loaded with griseofulvin nanoparticles. 
 
3.3.3.6 Scanning Electron Microscopy (SEM). Cross-sectional SEM images of all 
seven film formulations were taken in order to qualitatively assess the size and 
morphology of the embedded API particles (Figure 3.6). As can be clearly seen in all 
seven images, the GF nanoparticles were finely dispersed throughout the films with no 
visible signs of aggregation. This reinforces the assessment of the redispersion results in 
Sub-section 3.2.3.2 that the polymer matrix is able to physically stabilize the embedded 







Figure 3.6 Cross sectional SEM images of HPMC films loaded with griseofulvin 
nanoparticles made from polymer solutions containing (a) no plasticizer,                        
(b) 2.5% glycerin, (c) 5.0% glycerin, (d) 2.5% triacetin, (e) 5.0% triacetin, (f) 2.5% PEG, 








3.3.3.7 Long-term Stability of Films. In order to evaluate the ability of the film 
format to preserve drug nanoparticle size and enhanced dissolution over an extended 
period of time, redispersion and dissolution tests were performed for all formulations 
over the course of 6 months’ storage at 40 ºC and 75% RH. First, the long-term physical 
stability of the GF nanoparticles embedded within the polymer matrix was assessed via 
redispersion (Table 3.2). While there was some variation in the d10, d50, and d90 values of 
redispersed GF particles between formulations, little variation was observed within any 
of the seven film formulations during this time. This suggests that long-term stability of 
poorly water-soluble drug nanoparticles is indeed achievable in polymer strip films 
containing various plasticizers and plasticizer content. 
In order to investigate the impact of long-term storage on the dissolution rate of 
the films, Figure 3.7 shows dissolution curves for all seven film formulations after 0, 3, 
and 6 months of storage at 40 ºC and 75% RH. While some films exhibited variation in 
maximum percentage of GF released before and after storage, little statistical difference 
in dissolution rate was observed for most of the seven film formulations (Appendix A.1). 
This suggests that polymer films are capable of successfully stabilizing and releasing 






















































































0 10 20 30 40 50 60
Time (min)























2.5% Triacetin 2.5% PEG
5.0% Triacetin 5.0% PEG
 
Figure 3.7 Comparison of dissolution profiles for all films immediately after film 
preparation, after 3 months of storage at 40 ºC, 75% RH, and after 6 months of storage at 
40 ºC, 75% RH. Values are mean ± SD, n = 6. 
 
 Conclusions 3.4
The objective of this work was to investigate the impact of plasticizer and plasticizer 
concentration on various properties of strip films loaded with poorly water-soluble drug 
(GF) nanoparticles. Addition of any of the three plasticizers under investigation (glycerin, 
triacetin, and PEG-400) led to a depression of film glass transition temperature, a 
decrease in film tensile strength, and an increase in film elongation at break. However, in 
spite of these clear differences, there was little difference between the dissolution rates of 
the films, perhaps due to the robustness with which the drug nanoparticles were stabilized 
and dispersed. This suggests that film mechanical properties may be successfully 




drug release from the films. The similarity between dissolution rates of different films 
was observed even after the films were stored under stress conditions for six months, 
demonstrating that the consistency of drug release between formulations is preserved 
after long-term storage. In addition, the redispersibility of the embedded GF 
nanoparticles was also preserved after six months’ storage, demonstrating the long-term 
stability of the films. This consistency between films with different plasticizers and 
plasticizer concentrations will allow formulators the freedom to adjust the strength and 
elasticity of films containing poorly water-soluble drug without negatively impacting 






4 EFFECT OF FILM-FORMING POLYMER MOLECULAR WEIGHT___ 
 
 Introduction 4.1
One of the greatest strengths of the strip film format is its inherent versatility as a drug 
delivery platform. With excipients including the film-forming polymer, plasticizing 
agent, and various other additives, there is a wide array of formulation options available 
in strip film development, even for poorly water-soluble drugs. Exploration of this 
flexibility is made even more enticing by the relative simplicity of the film manufacture 
process as compared to the manufacture of more traditional solid dosage forms 
(Hoffmann et al., 2011), which has been the subject of recent literature. For instance, 
some have manipulated the mechanical properties of films containing poorly water-
soluble drug in both the amorphous (Panda et al., 2014) and crystalline states in Chapter 
3 by adjusting plasticizer and plasticizer concentration while attempting to preserve the 
enhanced dissolution rate of the drug. Others have investigated the use of viscosity-
enhancing agents, such as natural gums or superdisintegrants, for modulation of drug 
nanoparticle release from films (Krull et al., 2016b; Susarla et al., 2015), although both 
observed differences in film mechanical properties as well. However, to the best of the 
authors’ knowledge, a simple means of manipulating poorly water-soluble drug release 
from strip films without significantly affecting film mechanical properties has yet to be 
demonstrated. 
One particularly useful property of polymers as film-forming agents is the variety 
of molecular weights (MWs) available for a given polymer. Varying polymer MW has 




Ganorkar et al. (1999) observed slower insulin release from higher MW                         
N-isopropylacrylamide/butyl methacrylate/acrylic acid polymeric beads, noting a shift in 
controlling release mechanism from polymer erosion to drug diffusion. Mittal et al. 
(2007) observed a similar shift in controlling release mechanism from estradiol-loaded 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles with increasing PLGA MW. Rowe 
(1986) observed slower release of a propanolamine derivative from coated granules of 
ethylcellulose–hydroxypropyl methylcellulose (EC–HPMC) with higher MW EC, 
presumably due to cracks and flaws in the lower MW film coatings. Omelczuk and 
McGinity (1992) observed slower theophylline release from tablets made using higher 
MW grades of PLA up to ~138 kDa, above which no differences in drug release rate 
were observed. Marucci et al. (2013) observed slower release of metoprolol from pellets 
coated with hydroxypropyl cellulose–ethylcellulose (HPC–EC) using higher MW EC due 
to slower HPC leaching and, consequently, slower drug diffusion. Prodduturi et al. (2005) 
observed slower release of amorphous clotrimazole from higher MW poly(ethylene 
oxide) films produced via hot melt extrusion. Huang et al. (2013) observed slower water 
absorption and drug release from higher MW PLGA films loaded with amorphous 
paclitaxel. However, none of these studies investigated films containing poorly water-
soluble drug particles. In addition, existing literature suggests that film-forming polymer 
MW has a significant effect on film mechanical properties when the concentration of 
film-forming polymer is held constant (Huang et al., 2013; Lazaridou et al., 2003; Park et 
al., 1993). A simple means of manipulating drug release rate without significantly 





This chapter demonstrates that the release rate of poorly water-soluble drug 
nanoparticles from polymer films can be manipulated with minimal impact on film 
mechanical properties or nanoparticle redispersibility. 
 
 Experimental Procedures 4.2
Experimental procedures for the preparation of polymer films containing GF 
nanoparticles, film mechanical properties, TGA, and SEM are identical to their respective 
procedures described in Section 2.2. Experimental procedures for viscosity, GF particle 
size after milling and redispersed from films, determination of drug content and 
uniformity in films, and flow-through cell dissolution (USP IV) are identical to their 
respective procedures described in Section 3.2. 
4.2.1 Materials 
Griseofulvin (GF; Letco Medical, Decatur, AL) was selected as a model 
Biopharmaceutics Classification System (BCS) class II drug. Three different viscosity 
grades of hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV, MW   
~14 kDa; E50 Premium LV, MW ~21 kDa; E4M Premium, MW ~88 kDa; The Dow 
Chemical Company, Midland, MI) served as film-formers. E50 and E4M samples were 
generously donated by The Dow Chemical Company. HPMC-E15LV also served as a 
nanoparticle stabilizer during WSMM, along with the surfactant sodium dodecyl sulfate 
(SDS; Fisher Scientific, Pittsburgh, PA). Glycerin (Sigma–Aldrich, St. Louis, MO) was 
used as a film plasticizer. GF particle size reduction was performed by WSMM according 





4.2.2 Preparation Methods 
4.2.2.1 Preparation of GF Nanosuspension. GF nanosuspension was prepared via 
WSMM using a Netzsch mill (Microcer, Fine Particle Technology LLC, Exton, PA). 
Methods and stabilizer concentrations were selected according to previous optimization 
studies (Bilgili and Afolabi, 2012; Monteiro et al., 2013). The suspension consisted of 
10% GF dispersed in a stabilizer solution of 2.5% HPMC-E15LV and 0.5% SDS (all w/w 
wrt water), and was milled for 120 min. A single GF nanosuspension formulation was 
used across all film formulations, as opposed to using different polymer MWs for each 
film formulation, to ensure consistency in the size and morphology of the milled GF 
particles (for a thorough investigation of the effect of polymer MW in WSMM, readers 
are referred to Li et al. (2016)). This meant that the HPMC-E15LV stabilizer, which 
adsorbed onto the surface of the GF nanoparticles during milling, was present in all film 
precursors, including those that used E50 and E4M as film-formers. The resulting mass 
ratios of film-forming polymer to HPMC-E15LV stabilizer were ~9.9 for E50 film 
precursor formulations and ~3.5 for E4M film precursor formulations. 
4.2.2.2 Preparation of Film Precursor Suspension. As per Dow® protocol, 
polymer solutions were prepared by adding the appropriate amounts of HPMC and 
glycerin to water at 90 ºC, after which the solution was allowed to cool to room 
temperature under continuous magnetic stirring. Polymer concentrations were selected 
such that the polymer solutions were sufficiently viscous to ensure a uniform film while 
not too viscous to hinder mixing or casting. In order to account for this, as well as to 
minimize the effect of viscosity variation on film properties seen in previous work 




employed in which three target viscosity ranges were identified for study across all three 
HPMC grades: 9,000-10,000 cP (―Low‖), 11,000-13,000 cP (―Med‖), and              
19,000-25,000 cP (―High‖). This required careful selection of polymer concentrations in 
the polymer solution formulations by decreasing polymer concentration with increasing 
polymer MW, as seen in Table 4.1. The ratio of polymer-to-plasticizer was maintained 
within each trio of viscosity ranges, although this ratio had to be slightly increased with 
increasing viscosity to prevent over-plasticization in E4M films (3.0, 3.4, and 3.8, 
respectively). Each of the resulting polymer solutions was mixed with GF 
nanosuspension in a 2:1 ratio by mass using a Thinky ARE-310 planetary centrifugal 
mixer (Thinky, Laguna Hills, CA). Polymer solution and nanosuspension were mixed at 
2,000 rpm for 30 s, followed by 7 min of deaeration at 2,200 rpm, to form film precursor 
suspension. If bubbles were still present in the precursor suspension after mixing, the 
precursor was left overnight to settle before casting.  
Table 4.1 Composition of HPMC Polymer Solution Formulations and Low Shear       
(2.2 s
-1
) Room Temperature Viscosity of Polymer Solutions and Film Precursor 
















E15-Low E15 15.0 5.0 80.0 9,030 ± 190 7,120 ± 350 
E15-Med E15 17.0 5.0 78.0 11,190 ± 350 8,060 ± 1,960 
E15-High E15 19.0 5.0 76.0 N/M 10,250 ± 1,860 
E50-Low E50   9.6 3.2 87.2 9,570 ± 430 7,730 ± 200 
E50-Med E50 10.9 3.2 85.9 12,820 ± 370 10,240 ± 320 
E50-High E50 12.1 3.2 84.7 24,250 ± 830 9,070 ± 350 
E4M-Low E4M   3.3 1.1 95.6 9,710 ± 150 9,970 ± 1,290 
E4M-Med E4M   3.7 1.1 95.2 12,580 ± 370 14,700 ± 2,690 
E4M-High E4M   4.2 1.1 94.8 19,050 ± 330 17,010 ± 3,940 





4.2.3 Characterization Methods 
4.2.3.1 Real-time Surface Dissolution Imaging. A Sirius Surface Dissolution Imager 
(SDI) UV imaging system (Sirius Analytical Instruments Ltd., East Sussex, UK) was 
used to gain qualitative insight into the potential drug release mechanisms from films. 
The SDI employed an ActiPix™ D100 UV Area Imaging System (Paraytec Limited, 
York, UK) with the use of ActiPix™ D100 software (version 1.2, Paraytec Limited, 
York, UK). Images were recorded at 3.82 fps with sub-sampling every 10 min and 10 × 1 
horizontal binning (each pixel represents 7 × 7 µm). Imaging was performed at 214 nm 
with the use of a single wavelength filter (10 nm bandwidth) with a pulsed xenon lamp as 
the light source. A 62.0 × 7.0 × 3.0 mm (L × H × W, W being the path length) quartz 
dissolution cell was used to house the 3D printed sample holder which was custom-fit for 
the quartz cell. Flow was controlled using a syringe pump. 
Prior to data collection, dark images with the lamp turned off and reference 
images with blank SDS solution (5.4 mg/ml, also used for USP IV dissolution) were 
recorded for 10 s each for instrument calibration with the empty sample holder in place. 
After calibration, data collection was halted to allow for film sample insertion, at which 
point flow was stopped and the sample holder was removed. A circular film sample,        
2 mm in diameter, was secured on the surface of an inert support material placed inside a 
2.4 mm high, 2 mm diameter hollow stainless steel cylinder. The cylinder was then 
placed inside the bottom of the sample holder such that one surface of the film would be 
exposed to media flow (Figure 4.1), and the sample holder was re-inserted into the quartz 
cell. Once the sample holder was in place, the cell was filled with dissolution media 
before data collection and media flow at 0.2 µm/min were initiated. Media temperature 





Figure 4.1 SDI film sample holder schematic. 
 
4.2.3.2 Curve Fitting of Dissolution Profiles. In order to gain insight into the 
potential mechanisms of drug release from films, all dissolution profiles were fitted to the 
following five models: Equation (4.1), the zero order model, which predicts linear drug 
release with time, as one would expect from erosion-limited planar systems, where F is 
the percentage of drug dissolved at time t and k0 is a constant: 
 
 0F k t   (4.1) 
 
Equation (4.2), the first order model, which is commonly employed to describe drug 
release from reservoir sources (Gibaldi and Feldman, 1967) including drug particle 
dissolution (Noyes and Whitney, 1897), where k1 is a constant: 
 
  1100 1 k tF e    (4.2) 
   











Equation (4.3), the Higuchi equation, or square-root law, developed to describe drug 
release via diffusion from planar matrices (Higuchi, 1963), where kH is a constant: 
 
 HF k t   (4.3) 
 
Equation (4.4), the Korsmeyer–Peppas equation, or power law, designed to identify the 
controlling drug release mechanism of a given dosage (Korsmeyer et al., 1983; Peppas, 
1985), where kKP is a constant that incorporates geometric and structural characteristics of 
the system and n is the release exponent: 
 
 n
KPF k t   (4.4) 
 
and Equation (4.5), the Hixson–Crowell equation, or cube-root law, based on the 
relationship between the surface area and volume of a dissolving particle (Hixson and 





100 1 1 HCF k t    
  (4.5) 
 
These models were selected for both their basis in fundamental dissolution phenomena 





4.2.3.3 Statistical Analysis. Basic calculations were performed using Microsoft 
Excel
®
 (Microsoft Office 2010). Analysis of variance (ANOVA) and Tukey pairwise 
comparisons (two-tailed t-tests) were performed using Minitab
®
 (Minitab 17.3.1). 
Dissolution curve fitting was performed using a script written in Matlab
®
 (R2015b, 
Mathworks). Results for viscosity, mechanical properties, and dissolution profiles are 
expressed as mean ± SD (standard deviation) while content uniformity results are 
expressed as mean with RSD% (relative standard deviation). Dissolution profiles were 
compared to each other using similarity and difference factors (Boateng et al., 2012; 
Costa and Lobo, 2001). 
 
 Results and Discussion 4.3
4.3.1 Viscosity of Polymer Solutions and Precursor Suspensions 
Low shear (2.2 s
-1
) viscosity measurements for polymer solutions and film precursor 
suspensions were performed to mimic conditions of film casting (Table 4.1). Viscosity 
ranges fell within 9,000-9,600 cP, 11,200-12,800 cP, and 19,000-24,000 cP for ―low‖, 
―medium‖, and ―high‖ viscosity polymer solutions, respectively. As discussed in Sub-
section 4.2.2.2, this viscosity matching approach was necessary in lieu of keeping 
polymer concentrations constant to ensure film precursor suspensions were castable and 
did not spread or run upon casting. Appropriately selecting polymer concentrations 
within each viscosity range was also expected to minimize the impact of polymer 
solution viscosity on precursor suspension and film properties (Susarla et al., 2015; 
Susarla et al., 2013) when investigating the impact of film-forming polymer MW. Upon 




suspensions generally exhibited lower viscosities than their respective polymer solutions 
(7,100-10,000 cP, 8,000-14,000 cP, and 9,000-17,000 cP for ―low‖, ―medium‖, and 
―high‖, respectively). However, unlike the polymer solutions where viscosities within 
each class were roughly similar, film precursor suspension viscosity tended to increase 
slightly with increasing polymer MW, despite being mixed with the same ratio of GF 
nanosuspension. This may be the result of stronger GF nanoparticle interaction with 
higher MW HPMC (E4M) compared to lower MW HPMC (E15 and E50).  
4.3.2 GF Particle Size after Milling and Redispersed from Films 
Retaining poorly water-soluble drug nanoparticle size upon incorporation into and 
delivery from any solid dosage form is crucial to retaining the enhanced dissolution and 
bioavailability of the drug. In order to investigate the ability to recover GF nanoparticles 
from films, all formulations were subjected to redispersion tests in deionized water and 
the resulting PSDs were compared to that of the original GF nanosuspension. As seen in 
Figure 4.2 where PSD statistics are reported in the form of 10%, 50% (median), and 90% 
passing size (d10, d50, and d90, respectively), not only were GF nanoparticles recovered 
from all film formulations regardless of polymer MW or concentration, but most PSDs 
were practically identical to that of the original nanosuspension from which the GF 
nanoparticles were taken. Even in E4M films which exhibited slight increases in 
measured particle size, only E4M-Low showed any particles larger than 1 µm (< 5%) and 
none larger than 2 µm. These results demonstrate that poorly water-soluble drug 
nanoparticles can be successfully recovered from polymer films made using various 






























































Figure 4.2 Particle size statistics of GF nanosuspension and redispersed film samples. 
 
4.3.3 Film Characterization 
4.3.3.1 GF Content and Uniformity in Films. As in any pharmaceutical dosage 
form, consistency in dosing is critical. In order to assess drug content and uniformity of 
films, content uniformity tests were performed on all nine film formulations to evaluate 
thickness, mass of drug per unit area, and drug loading by wt% (Table 4.2). In order to 
better elucidate possible differences in uniformity between films, smaller sample sizes 
(~0.7 cm
2
) than the conventional film dosage (4-6 cm
2
) were used, resulting in larger than 
expected RSD%. That said, the majority of films still exhibited < 6% RSD in terms of 
film thickness and GF mass per unit area; in fact, all but one were < 3% RSD in terms of 
wt% GF. These results demonstrate the robustness of the film manufacture process to 





Table 4.2 Content Uniformity of HPMC Films with Different Polymer MWs and 
Concentrations. Values are an Average of 10 Samples ~0.7 cm
2
















E15-Low   91.6 5.2% 1.81 6.9% 13.7 2.5% 
E15-Med 114.2 4.1% 2.14 5.1% 13.7 1.1% 
E15-High 110.6 1.6% 1.93 3.2% 12.7 2.5% 
E50-Low   64.7 4.4% 1.64 5.2% 18.5 2.4% 
E50-Med   70.4 5.7% 1.78 4.9% 18.9 1.1% 
E50-High   71.9 3.8% 1.80 4.6% 19.1 2.9% 
E4M-Low   34.7 2.7% 1.97 3.3% 43.8 7.4% 
E4M-Med   41.4 6.7% 2.02 2.4% 38.3 2.8% 
E4M-High   38.5 5.1% 1.93 4.5% 42.0 2.1% 
 
The most obvious trends involve decreasing film thickness and increasing wt% 
GF with increasing polymer MW. Both of these are a direct result of a greater loss in 
moisture content during drying as a result of varying polymer concentration due to the 
necessity of a viscosity matching approach. Since all films were cast at the same        
1000 µm thickness but less polymer mass was required to achieve the same viscosity for 
high MW polymers (Table 4.1), higher MW polymer solutions and precursor suspensions 
contained greater water content. Consequently, more water, and therefore more mass, 
was available for evaporation during drying, resulting in thinner dry films with 
apparently greater GF loading by wt%. This is supported by the fact that the same trend 
was not observed for GF mass per unit area. Since every polymer solution was mixed 
with the same amount of GF nanosuspension, the mass of GF per unit area of film should 
fluctuate around a given value rather than increase or decrease with increasing polymer 
MW. It is also worth noting that drug loadings of up to 44 wt% were achieved simply by 
using a higher MW film-forming polymer. If an E4M film is prepared with the current 




achieve a dosage as high as 35 mg. The potential for higher dosage films containing 
poorly water-soluble drug nanoparticles will be the topic of a future study. 
4.3.3.2 Film Mechanical Properties. Mechanical properties of all nine film 
formulations are shown in Table 4.3. Here, two overarching effects were investigated: the 
effect of increasing polymer solution viscosity by increasing polymer concentration 
within each polymer MW class, and the effect of increasing polymer MW within each 
viscosity range. First, regarding increasing polymer solution viscosity, although there 
were slight increasing trends in TS, YS, YM, and EB overall within each MW class due 
to an increase in polymer concentration, most of these trends were not statistically 
significant (p < 0.05). While one might expect more significant increases in film strength 
and elongation with increasing polymer concentration across a wider range of polymer 
concentrations, the practical viscosity restrictions necessary for film casting in this work 
(~7,000-20,000 cP) inherently limited these potential differences. Next, regarding 
increasing polymer MW within each viscosity range, there was no statistical difference 
between the TS, YS, or EB of different MW grades (with the exceptions of the YS of 
E15-Low and the EBs of E15-Med and E4M-Med). However, there was a significant 
increase in YM and a noticeable decrease in EB with increasing polymer MW overall. 
That said, the variation in some of the film mechanical property measurements, 





Table 4.3 Mechanical Properties of Films with Different HPMC MWs and 










































































E4M-High 31.8 ± 5.4
ab







Values in each column that do not share a superscript are statistically different (p < 0.05). 
 
Without being limited to a fixed range of polymer solution viscosities, existing 
literature suggests that changes in film-forming polymer MW may lead to changes in the 
mechanical properties of the resulting films when the polymer concentration is held 
constant. Park et al. (1993) observed increases in film TS and YM with increasing 
polymer MW for methylcellulose (MC) and HPC. EB for MC films also increased with 
increasing MW, although EB for HPC films appeared to reach a maximum for an 
intermediate MW rather than increase monotonically. Lazaridou et al. (2003) also 
observed increasing film TS and EB with increasing pullulan MW. Huang et al. (2013) 
observed increases in film TS, YS, and YM with increasing PLGA MW, along with 
decreasing EB. However, while these trends appear to differ from the minimal changes in 
film mechanical properties with increasing polymer MW observed in this work, it is 
again worth mentioning that all of their films were prepared using equal concentrations of 
polymer regardless of their MW. In contrast, films in this work had to be prepared by 
matching polymer solution viscosity between film-forming polymer MWs, since equal 




viscous enough to form a uniform film or too viscous to cast. As such, there were two 
competing influences affecting film mechanical properties: increasing polymer MW and 
decreasing polymer concentration. Kennedy et al. (1994) attributed increases in the 
apparent modulus of films with increasing polymer MW to an increase in the number of 
entanglements per polymer chain, leading to additional impediments to strain. The 
frequency of such entanglements would decrease with a corresponding decrease in 
polymer concentration, offering a potential explanation for the lack of significant 
differences in most mechanical properties between films with differing HPMC MWs in 
this work. The frequency of polymer entanglements is further reduced by a corresponding 
increase in GF nanoparticle concentration in the dry film for higher polymer MW 
formulations (despite having the same GF loading by mass), which has also been shown 
to lead to a reduction in film mechanical properties (Krull et al., 2016b). As such, the 
inherent viscosity limits posed by the film manufacture process offer a convenient design 
space in which film-forming polymer MW can be safely adjusted with minimal impact on 
film mechanical properties. 
4.3.3.3 Dissolution. Dissolution profiles for all nine film formulations are shown in 
Figure 4.3, separated by viscosity range. E4M films for all three viscosity ranges 
exhibited significantly slower GF release than E15 and E50 films according to similarity 
and difference factors (Boateng et al., 2012; Costa and Lobo, 2001) (Appendix A.2). This 
slowing of GF release is even more significant given the fact that E4M films were only 
35-40 µm thick. In light of previous work which showed that film thickness is linearly 
proportional to time of 100% drug release in polymer films loaded with GF nanoparticles 




another film’s thickness to release twice as fast. In addition, E4M films within each 
viscosity range were prepared using approximately one-third and one-fifth the mass of 
polymer required for E50 and E15 films, respectively, to maintain similar viscosities. The 
fact that E4M films at all three viscosity ranges exhibited significantly slower release 
than E15 and E50 films despite their reduced thickness and polymer mass demonstrates 
the ability of the film-forming polymer MW to influence drug release from polymer films 
without significantly affecting film mechanical properties. That said, no such difference 
in GF release rate was observed between E15 and E50 films. Since their respective MWs 
are relatively similar (~14 kDa and ~21 kDa respectively) compared to that of E4M   
(~88 kDa), the similarity of the E15 and E50 dissolution profiles was likely due to the 
effect of higher polymer MW being unable to overcome the competing effects of less 





























































Figure 4.3 Comparison of dissolution profiles between films loaded with GF 
nanoparticles containing different HPMC MWs and concentrations. Values are          





To gain insight into potential drug release mechanisms, the dissolution profiles for 
all nine film formulations were fitted to zero order, first order, square-root (Higuchi), 
power law (Korsmeyer–Peppas), and cube-root (Hixson–Crowell) models. The fitting 
parameters and resulting adjusted R
2
 values for these fits are shown in Table 4.4 and 
Table 4.5, respectively. The Korsmeyer–Peppas equation was the best fit for all nine 
formulations with adjusted R
2
 values of 0.988 and above and a release exponent (n) 
above 1.0 in all cases, suggesting Super Case II transport. This, coupled with the lack of 
fit by models based on single drug release mechanisms, implies that drug nanoparticle 
release from these films cannot be explained by a single release mechanism. That said, 
the adjusted R
2
 values of zero order model fits approached those of the Korsmeyer–
Peppas model fits with increasing polymer concentration for all three polymer MWs, 
suggesting that polymer erosion may become the dominating release mechanism when 
high polymer concentrations are used in film formation, regardless of polymer MW. This 
is further supported by the fact that the release exponent of the fitted Korsmeyer–Peppas 
model approaches 1.0 with increasing polymer concentration. Others have also observed 
a shift in controlling drug release mechanism to drug diffusion with increasing polymer 
MW in other dosage forms, including polymeric beads (Ramkissoon-Ganorkar et al., 








Table 4.4 Fitting Parameters Generated by Fitting Dissolution Curves from GF 
Nanoparticle-loaded HPMC Films of Varying Polymer MW and Concentration to 
Various Dissolution Models 
 
Zero order First order Higuchi Korsmeyer–Peppas Hixson–Crowell 






) n (-) kHC (min
-1
) 
E15-Low 3.95 0.052 12.7 1.56 1.37 0.0158 
E15-Med 3.68 0.048 12.0 2.39 1.17 0.0147 
E15-High 1.24 0.016   7.0 0.85 1.10 0.0050 
E50-Low 2.50 0.032   9.7 0.63 1.47 0.0098 
E50-Med 3.75 0.049 12.1 1.79 1.29 0.0149 
E50-High 1.63 0.021   8.1 1.00 1.15 0.0066 
E4M-Low 2.49 0.030   8.8 0.43 1.64 0.0095 
E4M-Med 3.21 0.043 11.6 1.89 1.19 0.0130 
E4M-High 1.68 0.022   8.1 1.19 1.11 0.0067 
 
Table 4.5 Adjusted R
2
 Values Generated by Fitting Dissolution Curves from GF 
Nanoparticle-loaded HPMC Films of Varying Polymer MW and Concentration to 
Various Dissolution Models 
Formulation Zero order First order Higuchi Korsmeyer–Peppas Hixson–Crowell 
E15-Low 0.951 0.876 0.685 0.991 0.903 
E15-Med 0.984 0.934 0.749 0.995 0.954 
E15-High 0.987 0.952 0.784 0.991 0.967 
E50-Low 0.937 0.864 0.670 0.993 0.889 
E50-Med 0.963 0.900 0.707 0.991 0.924 
E50-High 0.980 0.939 0.764 0.988 0.956 
E4M-Low 0.912 0.846 0.634 0.996 0.868 
E4M-Med 0.981 0.923 0.745 0.994 0.946 
E4M-High 0.990 0.953 0.784 0.994 0.969 
 
As a visual complement to conventional film dissolution studies and analysis, 
surface dissolution images for low viscosity films are shown in Figure 4.4. E15 films 
appeared to dissolve readily with little swelling, whereas E50 and E4M films exhibited 
significant amounts of swelling due to their higher polymer MW, as indicated by the 
large bump that developed directly above the film samples inside the SDI. This swelling 
is exemplified by the fact that films made with polymers of increasing MW produced 




(2012) also observed a similar increase in extent of swelling between compacts of HPMC 
viscosity grades equivalent to E15 and E50 using the SDI. It should be noted that these 
images merely provide visual insight into the film dissolution process and do not 
necessarily indicate rate of drug release. For instance, although the swelling in E50 films 
was clearly visible in the SDI while little swelling was observed in E15 films, both films 
exhibited similar rates of drug release in the USP IV due to the confounding effects of 
differing polymer mass and film thickness. That said, the SDI images confirm the 
presence of more significant swelling in higher MW polymer films, even with a 
corresponding reduction in film thickness. 
 
Figure 4.4 Surface dissolution snapshots of low viscosity film formulations. Blue 
indicates absence of drug while warmer colors indicate higher concentrations of drug 
(note: the semicircle at the top of the 60 min snapshot of E50-Low is an air bubble, not a 
part of the film sample). 
 
4.3.3.4 Thermogravimetric Analysis. All nine film formulations were subjected to 
TGA and the resulting thermograms are shown in Figure 4.5. All films exhibited a weight 
loss between 2% and 6% up to 100 ºC, most likely due to the loss of water. Increasing the 
MW of the film-forming polymer led to a significant decrease in film water content 














viscosity within the range of investigation had no significant effect on film water content 
(3.7% for Low, 4.0% for Med, 4.0% for High; p < 0.05). This trend of decreasing water 
content with increasing polymer MW is even more significant given that film precursor 
suspensions containing higher MW HPMC had more water content before drying than 
those made with lower MW HPMC (Table 4.1). The significant weight loss following   
15 min of exposure to 150 ºC was likely due to the loss of the plasticizer, glycerin. The 
average weight loss during this time was ~4% across all films with no significant trend 























































Figure 4.5 TGA curves for films with different HPMC MWs and concentrations loaded 





4.3.3.5 Scanning Electron Microscopy. In order to qualitatively assess the size and 
morphology of the GF nanoparticles embedded within the films, cross-sectional SEM 
images were taken of all nine film formulations (Figure 4.6). Finely dispersed primary 
GF nanoparticles can be observed throughout all nine film formulations with no visual 
indications of agglomeration, which substantiates the redispersion results discussed in 
Section 4.3.2. This further supports that poorly water-soluble drug nanoparticles can be 
physically stabilized without aggregation within the polymer matrix of the films despite 
variations in film-forming polymer concentration and MW. 
 
 
Figure 4.6 Cross-sectional SEM images of (a) E15-Low, (b) E15-Med, (c) E15-High,  
(d) E50-Low, (e) E50-Med, (f) E50-High, (g) E4M-Low, (h) E4M-Med, and                  
(i) E4M-High films containing GF nanoparticles. Magnification of 50,000× was used for 







Figure 4.6 (Continued) Cross-sectional SEM images of (a) E15-Low, (b) E15-Med, (c) 
E15-High, (d) E50-Low, (e) E50-Med, (f) E50-High, (g) E4M-Low, (h) E4M-Med, and 
(i) E4M-High films containing GF nanoparticles. Magnification of 50,000× was used for 









The objective of this work was to investigate the impact of polymer MW and 
concentration on the properties and dissolution of polymer films loaded with poorly 
water-soluble drug nanoparticles. A polymer solution viscosity matching approach was 
necessary in order to ensure film precursor suspensions were castable and to minimize 
the influence of viscosity on the resulting films. Higher MW E4M films exhibited 
significantly slower drug release than lower MW E15 and E50 films across three 
viscosity ranges despite being formed with less polymer mass, which resulted in thinner 
films. However, despite the noticeable differences in dissolution rate between films made 
with different polymer MWs within each viscosity range, the respective differences in TS 
and EB between the same films were relatively minor. This suggests that the release rate 
of poorly water-soluble drug can be successfully controlled by adjusting film-forming 
polymer MW with little impact on the mechanical properties of the films if polymer 
solution viscosity is maintained between formulations. In addition, good content 
uniformity and nanoparticle redispersibility can be achieved using various film-forming 





5 EFFECT OF DRUG LOADING___ 
 
 Introduction 5.1
One perceived limitation shared by all means of incorporating poorly water-soluble drug 
into films is the existence of an inherent limitation on drug loading (Borges et al., 2015b; 
Dixit and Puthli, 2009; Hoffmann et al., 2011). While high drug loading in films is 
already difficult to achieve due to their small size, the means of incorporating drug into 
films can impose even greater limitations. Since a traditional strip film dosage only 
contains a fraction of the total mass of a typical tablet or pill, the amount of drug that can 
be conceivably loaded into a traditional strip film dosage cannot practically match the 
dosages available in tablets and capsules. In addition, the standard techniques by which 
poorly water-soluble drugs are incorporated into strip films further restrict the amount of 
drug that can be loaded into a film dosage, typically up to 30 wt%. In hot melt extruded 
films, the dissolution rate enhancement of the drug hinges on the stability of the 
amorphous solid dispersion during cooling and storage. This becomes increasingly 
difficult with increasing drug loading, resulting in uncontrolled crystallization if the drug 
loading is too high (Serajuddin, 1999). Similarly, organic solvent casting relies on the 
stability of drug in the amorphous form, specifically after the solvent in which the drug is 
dissolved is driven out of the film during drying. If the drug loading in solvent cast films 
is too high, they too will experience uncontrolled drug crystallization, resulting in a loss 
of drug dissolution rate enhancement (Hoffmann et al., 2011). Coupled with a drug 




restrictions on drug loading have made achieving even moderate dosages in strip films a 
significant challenge. 
Inclusion of engineered drug particles into strip films over the last few years has 
revealed the potential for higher drug loading in films, although the subject has yet to be 
fully explored. The majority of work in this area has either focused on establishing a 
means of particle engineering that is suitable for incorporation into the film platform 
(Beck et al., 2013; Bhakay et al., 2016; Prodduturi et al., 2005; Sievens-Figueroa et al., 
2012a; Visser et al., 2015) or the impact of critical material attributes (CMAs) on their 
performance (Krull et al., 2016b; Susarla et al., 2015). In most cases, drug loading in 
films was kept below 20 wt% with none above 30 wt%, presumably to avoid potential 
confounding influences of high drug loading on other experimental factors under 
investigation. Woertz and Kleinebudde (2015) claimed to have prepared ―acceptable 
films‖ with as high as 50 mg of homogenized ibuprofen in a 6 cm
2
 dosage, but neglected 
to demonstrate acceptable mechanical properties or dissolution rates for their films. 
Steiner et al. (2016) demonstrated HPMC films with up to 45 wt% WSMM naproxen 
nanoparticles that exhibited ―good‖ mechanical properties, above which films became too 
stiff for practical application, although they did not investigate dissolution rate. The 
potential for higher drug loading (40 wt%) in films containing WSMM griseofulvin 
nanoparticles prepared with high molecular weight (MW) polymer in passing in Chapter 
4 when investigating the impact of polymer MW. However, to this point, no study has 
been able to demonstrate good mechanical properties and enhanced poorly water-soluble 




This chapter investigates the effect of high loadings of poorly water-soluble drugs 
on polymer strip films, including mechanical properties and drug dissolution rates. 
 
 Experimental Procedures 5.2
Experimental procedures for the preparation of polymer films containing GF 
nanoparticles, film mechanical properties, TGA, and SEM are identical to their respective 
procedures described in Section 2.2. Experimental procedures for viscosity, GF particle 
size after milling and redispersed from films, determination of drug content and 
uniformity in films, and flow-through cell dissolution (USP IV) are identical to their 
respective procedures described in Section 3.2. Experimental procedures for long-term 
stability of films and statistical analysis are identical to their respective procedures 
described in Section 4.2. 
5.2.1 Materials 
Griseofulvin (GF; Letco Medical, Decatur, AL) was used as a model BCS class II drug. 
Hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV and Methocel E4M 
Premium, The Dow Chemical Company, Midland, MI) served as the film-forming 
polymer. HPMC-E15LV also served as a nanoparticle stabilizer in suspension, along with 
the surfactant sodium dodecyl sulfate (SDS; Fisher Scientific, Pittsburgh, PA). Glycerin 
(Sigma–Aldrich, St. Louis, MO) was used as a film plasticizer. GF particle size reduction 
was performed by wet stirred media milling (WSMM) according to Sub-section 5.2.2.1. 





5.2.2 Preparation Methods 
5.2.2.1 Preparation of GF Nanosuspensions. GF nanosuspensions were prepared 
via wet stirred media milling (WSMM) using a Netzsch mill (Microcer, Fine particle 
technology LLC, Exton, PA). Methods and stabilizer concentrations were selected 
according to previous optimization studies (Bilgili and Afolabi, 2012; Monteiro et al., 
2013). Suspensions consisted of 10%, 20%, or 30% GF dispersed in a stabilizer solution 
of 2.5% HPMC-E15LV and 0.5% SDS (all w/w wrt water). All three suspensions were 
milled for 120 min. 
5.2.2.2 Preparation of Polymer Solutions and Film Precursor Suspensions. 
Formulations for film-forming polymer solutions and film precursor suspensions are 
listed in Table 5.1. Polymer and plasticizer concentrations for polymer solutions were 
selected in such a way that all resulting film precursor formulations would be castable but 
not spread during drying (target viscosity range of 5,000-12,000 cP). This was 
accomplished using a viscosity matching approach for polymer solution preparation 
outlined in Sub-section 4.2.2.2 for E15 and E4M polymer solutions, represented by 0’s in 
Table 5.1. Polymer solutions were prepared by adding the appropriate amounts of HPMC 
and plasticizer to water at 90 ºC, after which the solution was allowed to cool to room 
temperature under continuous magnetic stirring. Polymer solutions were mixed with GF 
nanosuspensions using a Thinky ARE-310 planetary centrifugal mixer (Thinky, Laguna 
Hills, CA) at 2,000 rpm for 30 s, followed by 7 min of deaeration at 2,200 rpm, to form 
film precursor suspensions. If bubbles were still present in the precursor suspension after 




























DL0-15 E15 N/A N/A N/A 15.0% 5.0% N/A 80.0% 
DL1-15 E15 10% 3.6 1.9% 12.2% 3.9% 0.10% 81.8% 
DL2-15 E15 10% 1.5 3.5%   9.9% 3.0% 0.18% 83.4% 
DL3-15 E15 20% 3.0 4.1% 11.8% 3.8% 0.11% 80.3% 
DL4-15 E15 20% 1.6 6.2% 10.1% 3.1% 0.17% 80.5% 
DL5-15 E15 30% 2.3 6.8% 11.2% 3.5% 0.13% 78.6% 
DL6-15 E15 30% 1.4 9.4%   9.7% 2.9% 0.18% 78.0% 
DL0-4M E4M N/A N/A N/A   3.3% 1.1% N/A 95.6% 
DL1-4M E4M 10% 3.6 1.9%   3.1% 0.9% 0.10% 94.1% 
DL2-4M E4M 10% 1.5 3.5%   2.9% 0.7% 0.18% 92.8% 
DL3-4M E4M 20% 3.0 4.1%   3.0% 0.8% 0.11% 92.0% 
DL4-4M E4M 20% 1.6 6.2%   2.9% 0.7% 0.17% 90.1% 
DL5-4M E4M 30% 2.3 6.8%   3.0% 0.8% 0.13% 89.5% 
 
Drug loadings in film precursor suspensions were adjusted by varying the drug 
concentration in WSMM nanosuspensions and polymer-to-nanosuspension mixing ratios 
(Table 5.1). This combination of factors was necessary in order to ensure the resulting 
film precursor suspensions were within the castable viscosity range. E15 formulations 
were designed to achieve the following target GF loadings in their respective dry films: 
10 wt% for DL1-15, 20 wt% for DL2-15 and DL3-15, 35 wt% for DL4-15 and DL5-15, 
and 50 wt% for DL6-15. Similar drug loadings for DL2/3 and DL4/5 were chosen to 
observe the effects, if any, of adding GF nanoparticles from WSMM suspensions with 
different drug concentrations. Polymer-to-nanosuspension ratios were kept the same 
across both E15 and E4M formulations for ease of comparison. DL6-4M produced films 







 Results and Discussion 5.3
5.3.1 Viscosity of Polymer Solutions and Precursor Suspensions 
Low shear (2.2 s
-1
) viscosity measurements for polymer solutions and film precursor 
suspensions, performed with the objective of mimicking conditions of film casting, are 
presented in Figure 5.1. As explained in Sub-section 5.2.2.2, E15 and E4M polymer 
solutions (DL0-15 and DL0-4M, respectively) were formulated to have similar viscosities 
of ~12,000 cP so that, upon mixture with GF nanosuspension, all of the resulting film 
precursor formulations would be castable. Upon dilution with GF nanosuspension, the 
viscosity of the resulting film precursor suspensions generally decreased, more so for 
precursors with lower polymer-to-nanosuspension mixing ratios. It is also worth noting 
that GF nanosuspensions with greater solids content (30 wt% GF > 20% > 10%) were 
more viscous, leading to more viscous precursors prepared from higher drug loading 
nanosuspensions. For the same polymer-to-nanosuspension mixing ratios, E4M 
precursors generally exhibited greater viscosities than their respective E15 counterparts, 










































































Figure 5.1 Low shear (2.2 s
-1
) room temperature viscosity of polymer solutions and film 
precursor suspensions. 
 
5.3.2 Scanning Electron Microscopy (SEM) 
Cross sectional SEM images of all films were taken to qualitatively assess the size and 
morphology of the embedded GF nanoparticles (Figure 5.2). Finely dispersed GF 
nanoparticles were observed in all images, including both E15 and E4M films. This 
suggests that negligible drug nanoparticle aggregation within the film and uniform 
dispersion of embedded GF nanoparticles throughout the HPMC matrix is indeed 






Figure 5.2 Cross sectional SEM images of the following HPMC films with various GF 
nanoparticle loadings: (a) DL1-15, (b) DL2-15, (c) DL3-15, (d) DL4-15, (e) DL5-15,    









Figure 5.2 (Continued) Cross sectional SEM images of the following HPMC films with 
various GF nanoparticle loadings: (a) DL1-15, (b) DL2-15, (c) DL3-15, (d) DL4-15,     









5.3.3 GF Particle Size After Milling and Redispersed from Films 
Since poorly water-soluble drug particles naturally exhibit slow dissolution rates, it is 
critical that the WSMM nanoparticles do not aggregate upon incorporation into or 
delivery from films, as their enhanced dissolution rate would be lost. In order to 
investigate the ability of the film format to stabilize and deliver poorly water soluble drug 
nanoparticles, even with high drug loading, films were tested for nanoparticle 
redispersibility in water, and the size distributions of the GF particles redispersed from 
films were compared to those of the nanosuspensions from which the GF nanoparticles 
were originally taken. Redispersion tests were performed on all films on the day of 
preparation, as well as after 3 and 6 months of storage under stress conditions (40 ºC, 
75% RH) to assess long-term stability (stability results discussed in Section 5.3.8). 
Particle size distribution results, reported as 10%, 50% (median), and 90% passing sizes 
(d10, d50, and d90, respectively), are shown in Figure 5.3, organized by the WSMM 



















































































































From 20% GF suspension From 30% GF suspension
 
Figure 5.3 d10, d50 and d90 of GF nanoparticles in suspension and redispersed from 
HPMC-E15 and E4M films of varying API loading after 0, 3, and 6 months’ storage at  
40 ºC and 75% RH. 
 
The size of the original GF nanoparticles was recovered from all HPMC-E15 
films. The same nanoparticle redispersibility was observed in HPMC-E4M films up to 
about 50 wt% drug loading (DL2-4M), above which original nanoparticle size could no 
longer be immediately recovered upon redispersion in water. In fact, coarse drug–




for DL3-4M, DL4-4M, and DL5-4M films, appearing as undissolved film clusters after 
the film had physically broken apart during vortex mixing, rather than appearing to grow 
from suspended particles. However, as shown in the cross sectional SEM images (Section 
5.3.2), the GF nanoparticles are well dispersed and stabilized within all films, even those 
with high drug loading. Therefore, it is likely that the existence and slow dissolution of 
these drug–polymer agglomerates is due to interactions between the GF nanoparticles and 
HPMC-E4M during redispersion, rather than GF nanoparticle aggregation during film 
formation. Although by a different mechanism (flocculation), similar behavior was 
reported by Wong and Bodmeier (1996) in ethyl cellulose dispersions with HPMC. They 
observed flocculation at lower HPMC concentrations in dispersions with higher MW 
HPMC and higher poorly water-soluble solids content (ethyl cellulose), similar to how 
drug–polymer agglomerates were only observed upon redispersion from high MW 
HPMC films (E4M) above a certain GF loading (> 50 wt%) in this study. 
5.3.4 GF Content and Uniformity in Films 
Content uniformity tests were performed on all films in order to assess their drug content 
and uniformity. These results, shown in Table 5.2, are expressed in terms of film 
thickness, mass of GF per unit area, and GF loading by wt%. In spite of using a small 
sample size (roughly 1/10
th
 the size of a typical dose) to better elucidate potential 
differences between films, all HPMC-E15 films exhibited very good uniformity in terms 
of wt% GF (< 1% RSD) and mg GF/cm
2
 (most ~3% RSD). HPMC-E4M films, on the 
other hand, exhibited greater variability for both, due in part to their decreased thickness. 
Although all films were cast to be 1000 μm thick before drying, precursor suspensions 




These differences resulted in thinner films for precursors with higher starting water 
concentrations, as they had less solids content, in line with the results presented in Sub-
section 4.3.3.1. Consequently, although E15 and E4M precursors of the same number 
(e.g., DL1-15 and DL1-4M) contained roughly the same concentration of GF 
nanoparticles before drying, greater mass loss during drying drove up the percentage of 
GF remaining in the E4M films (despite having the same loading by mass per unit area). 
















DL1-15   97.2 2.8%   9.1 0.9% 1.22 4.1% 
DL2-15   85.1 3.4% 19.0 0.6% 2.22 3.4% 
DL3-15 109.0 2.5% 20.9 0.6% 3.18 2.9% 
DL4-15 108.8 4.4% 34.6 0.4% 5.29 3.3% 
DL5-15 122.9 2.1% 37.6 0.3% 6.08 2.9% 
DL6-15 127.4 4.0% 49.4 0.3% 8.61 4.8% 
DL1-4M   27.8 5.6% 30.5 4.6% 1.17 7.2% 
DL2-4M   40.1 6.6% 51.4 0.6% 2.87 5.0% 
DL3-4M   45.6 6.1% 56.4 3.4% 3.50 6.6% 
DL4-4M   57.3 5.7% 69.2 1.4% 5.54 4.8% 
DL5-4M   65.6 6.7% 72.8 0.3% 6.04 3.9% 
 
5.3.5 Film Mechanical Properties 
TS, YS, YM, and EB were measured for each film, with the exception of DL5-4M which 
was too brittle for texture analysis. As can be seen in Table 5.3, films generally exhibited 
TS between 35-45 MPa and YS between 30-40 MPa, demonstrating good mechanical 
strength regardless of GF nanoparticle loading. There was no observable trend in YM for 
E15 films with increasing GF nanoparticle loading, while YM appeared to increase 
significantly in E4M films prepared by suspensions with lower polymer-to-




dramatically with increasing drug nanoparticle loading above ~40 wt% GF. It is no 
surprise that one of the greatest challenges posed by high drug loading in films is 
simultaneously maintaining good mechanical properties for manufacture and patient 
compliance. Typically, film-forming polymer mass must be reduced to account for higher 
drug loading, reducing the integrity of the resulting film matrix. Although there are 
currently no fixed guidelines regarding acceptable mechanical properties of 
pharmaceutical films (Hoffmann et al., 2011), the brittleness of high drug loading films 
which exhibited EB < 5% was readily apparent as they were being handled. Steiner et al. 
(2016) also observed brittleness in poorly water-soluble drug nanoparticle-loaded films 
with similarly high drug loading using a lower MW grade of HPMC as film-forming 
polymer. Although it may be possible to push the maximum drug particle loading in films 
above 45-50 wt% while maintaining acceptable film mechanical properties with more 
thorough formulation development, such as modulation of plasticizer content described in 
Chapter 3, these results suggest that film brittleness is a major hurdle to overcome to 
achieve higher drug particle loadings in strip films for practical use. 


















DL2-15 40.7 ± 0.1
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*DL5-4M not listed as it was impossible to cut strips due to film brittleness 
a-d




When comparing directly between HPMC MWs for films with the same drug 
loading by mass (e.g. DL1-15 and DL1-4M), the observed trends are in line with those 
presented in Sub-section 4.3.3.2 which also incorporated a polymer solution viscosity 
matching approach. There was no statistical difference between the TS or YS of E15 and 
E4M films for most drug loadings (with the exception of TS for DL1). However, YM 
was generally lower and EB was generally higher for E15 than for E4M, suggesting that 
E4M films were more brittle than E15 films. As in the previous study, it is worth noting 
that E4M polymer solution was prepared using a lower concentration of HPMC to match 
the viscosity of E15 polymer solution to ensure the precursor was castable. As a result, 
the lower HPMC concentration (and, consequently, higher GF nanoparticle loading by 




Dissolution curves for fresh films are shown in Figure 5.4, separated by HPMC MW 
grade. The extent of drug release relative to the estimated drug content established in 
Sub-section 5.3.4 decreased slightly with increasing GF loading, likely due to increasing 
deviation from sink conditions. There was a clear increasing trend in total release time for 
both HPMC-E15 and HPMC-E4M films with increasing drug nanoparticle loading up to 
~50 wt% GF. Additional time required to achieve 100% drug release may be partially 
attributed to other factors, including increasing film thickness (Krull et al., 2016b) and 
varying polymer concentration as seen in Sub-section 4.3.3.3 with increasing drug 




DL3-4M, DL4-4M, and DL5-4M exhibited statistically similar release rates according to 
similarity and difference factors (Boateng et al., 2012; Costa and Lobo, 2001)   
(Appendix A.3). These films also exhibited poor GF nanoparticle redispersibility (Section 
5.3.3) and polymer–drug agglomerates were visible upon film disintegration during 
dissolution testing similar to those observed in redispersion tests. It appears likely that, 
above 50 wt% drug nanoparticle loading, the dissolution of these polymer–drug 
agglomerates became the controlling drug release mechanism, particularly for high MW 
polymers, resulting in similar release rates for all E4M films with high drug loading. 
When directly comparing drug release rates of E15 and E4M films with similar drug 
loading by mass (e.g. DL1-15 and DL1-4M), the higher MW E4M films appear to release 
more slowly than their E15 counterparts for all drug loadings, in line with the results 


















































Figure 5.4 Dissolution profiles of HPMC (a) E15 and (b) E4M films with various GF 
nanoparticle loadings. 
 
5.3.7 Thermogravimetric Analysis (TGA) 
TGA curves for E15 and E4M films are shown in Figure 5.5a and Figure 5.5b, 
respectively. All films exhibited significant mass loss up to 110 ºC, most likely due to the 
loss of water. E15 films exhibited the greatest such loss on average (~6.5 wt%) compared 




than E4M precursor suspensions when cast. In addition, films with higher GF 
nanoparticle loading generally exhibited less weight loss during this time, suggesting 
lower moisture content. This may be due to the fact that films with higher GF 
concentrations exhibit greater overall hydrophobicity, driving out additional moisture 
during drying, resulting in films with less moisture content. Films with higher GF 
nanoparticle loading also contained lower concentrations of hydrophilic HPMC, which is 
expected to retain some moisture even after the film dries, likely resulting in lower 
moisture content. The significant weight loss after holding at 150 ºC for 15 min was most 
likely due to the loss of the plasticizer glycerin. Relative weight loss between film 
formulations during this time was generally in line with the plasticizer concentrations in 










































Figure 5.5 TGA curves for HPMC (a) E15 and (b) E4M films with various GF 
nanoparticle loadings. 
 
5.3.8 Long-term Stability of Films 
Redispersion and dissolution tests were performed for all film formulations over the 
course of six months’ storage at 40 ºC and 75% RH to simulate the effects of long-term 
storage on the ability of the film format to preserve drug nanoparticle size and enhanced 




nanoparticles from films via redispersion in water was assessed (Figure 5.3). Aside from 
order of magnitude increases in the d90 of a select three films for 3 month samples only 
(DL1-4M, DL4-15, DL6-15), there was no observable impact of long-term storage on GF 
nanoparticle redispersibility from films. The ability to recover GF nanoparticles after      
6 months of storage under stress conditions was demonstrated for all E15 films and E4M 
films with 50 wt% drug loading or less. Interestingly, long-term storage did not appear to 
influence the inability to immediately recover GF nanoparticles from E4M films with 
higher drug loading, as the particle size statistics for such films did not appear to deviate 
significantly after storage. 
Dissolution tests were also performed on films following 0, 3, and 6 months’ 
storage at 40 ºC and 75% RH in order to investigate the effect of long-term storage on the 
drug dissolution rate from films. Four of six E15 film formulations exhibited similar rates 
of drug release after 3 and 6 months’ storage according to similarity and difference 
factors (Appendix A.3) while the remaining two formulations, DL2-15 and DL6-15, were 
not drastically different (Figure 5.6). This suggests that drug release rates from E15 films 
are relatively stable, even after long-term storage, for a wide range of drug nanoparticle 
loadings. On the other hand, while E4M films exhibited similar release profiles after       
3 months’ storage, they appeared to release drug more quickly after 6 months of storage, 
particularly from high drug loading films for which polymer–drug agglomerates were 
observed during initial redispersion and dissolution tests (Figure 5.7). It is possible that 
prolonged exposure to high humidity weakened the interaction between HPMC-E4M and 
GF nanoparticles within the film, resulting in faster dissolution of the polymer–drug 





















































































































Figure 5.6 Comparison of dissolution profiles for E15 films immediately after film 
preparation, after 3 months of storage at 40 °C, 75% RH, and after 6 months of storage at 




































































































Figure 5.7 Comparison of dissolution profiles for E4M films immediately after film 
preparation, after 3 months of storage at 40 °C, 75% RH, and after 6 months of storage at 
40 °C, 75% RH. Values are mean ± SD, n = 6. 
 
 Conclusions 5.4
The objective of this work was to investigate the capability of producing strip film 
dosages containing high loadings of poorly water-soluble drug nanoparticles with good 
mechanical properties that retain the enhanced dissolution rate of the drug nanoparticles. 




films, respectively, films with drug loadings above 40-50 wt% were unacceptably brittle, 
imposing a practical drug loading limitation for films with good mechanical properties. In 
addition, undissolved polymer–drug agglomerates were observed upon redispersion and 
dissolution from E4M films with drug loadings above 50 wt%, severely limiting the 
ability to recover the embedded GF nanoparticles and retain their enhanced dissolution 
upon delivery. In spite of these challenges, all film formulations exhibited good content 
uniformity (6% RSD or less) and were able to preserve the size and morphology of the 
GF nanoparticles. These results suggest that the greatest barriers to producing 
pharmaceutical films with high loadings of poorly water-soluble drug nanoparticles are 
overcoming poor film mechanical properties and ensuring recovery of the embedded drug 






6 DISSOLUTION MODEL FOR DRUG PARTICLE-LADEN FILMS___ 
 
 Introduction 6.1
One of the most crucial elements when developing a pharmaceutical product is the ability 
to deliver the appropriate dose at the correct time. This holds true regardless of the 
dosage form, from tablets to films and everything in-between. Drug release from 
pharmaceutical systems is commonly controlled by embedding the drug in a polymeric 
matrix. In doing so, the polymer generally serves as a diffusion barrier for the embedded 
drug, restricting its release from the dosage form in a controllable manner (Langer and 
Peppas, 1981). This predictability led to extensive use of simple empirical models such as 
the Higuchi equation (Higuchi, 1963) for fitting drug release from polymer matrices 
which did not swell or erode (Peppas, 1985). In addition, these simple models also 
assume the drug incorporated into the system is water-soluble and that the drug dissolves 
immediately upon exposure to solvent. However, in systems with swellable/erodible 
polymer or poorly water-soluble drugs, these simple models break down, necessitating 
the use of more complex models. Improved understanding of the mechanisms governing 
controlled release from pharmaceutical products and advancements in computational 
efficiency have paved the way for the development of mathematical models that predict 
the rate of drug release from a given system. Such predictive models have typically been 
used to simulate controlled or extended release, as precision dosing is critical for such 
applications, but this restriction allows for the implementation of certain assumptions that 




While predictive modeling for film dissolution has been a growing topic of 
discussion in recent literature, few proposed models, if any, have been able to encompass 
all of the nuances present in poorly water-soluble particle-loaded polymer films for 
immediate release. Siepmann et al. (1999) developed a Fickian diffusion-based mass 
transport model for swellable polymer tablets containing water-soluble drug and poorly-
soluble drug (Siepmann et al., 2013) assuming instantaneous absorption of water. 
Frenning (2003) modeled drug particle dissolution from a non-swellable, non-erodible 
planar matrix assuming instant solvent absorption. Wu et al. (2005) simulated release of a 
water-soluble drug from swellable/erodible polymer tablets while taking water 
penetration into consideration and only considering polymer dissolution from the tablet 
surface. Borgquist et al. (2006) simulated release of both soluble and poorly-soluble drug 
from swellable/erodible poly (ethylene oxide) tablets for extended release (10-30 h), only 
considering polymer dissolution from the tablet surface. Cabrera et al. (2006) modeled 
release of arbitrarily placed drug particles from planar polymeric systems assuming a 
non-swellable, non-erodible matrix, averaging drug particle concentration within layers 
as continuous drug dissolution sources. Zhang et al. (2006) developed a diffusion–
dissolution model for poorly water-soluble drug particle release from polymeric 
microspheres considering a moving dissolution boundary and particle size distribution. 
Xiang and McHugh (2011) developed a generalized diffusion–dissolution model for non-
swellable, non-erodible polymer matrices containing amorphous drug and dispersed drug 
particles. However, most of these models focus on diffusion as the limiting drug release 
mechanism and none of them considered polymer swelling/erosion, poorly water-soluble 




This chapter introduces a predictive mathematical model for poorly water-soluble 
drug particle release from polymer films developed from first principles and compares 
simulated dissolution profiles to experimental data from previous chapters. 
 
 Mathematical Model 6.2
A schematic of the model for drug nanoparticle release from a film matrix is shown in 
Figure 6.1. The film has an initial thickness L = L0 at time t = 0. While the depicted 
example shows an impermeable wall boundary at x = 0, the same model is also applicable 
if the wall boundary is replaced by an identical film of equal thickness on the opposite 
side of the origin due to symmetry, in which case L becomes the half-thickness.  
 
Figure 6.1 Process schematic of drug nanoparticle release from film matrix. 
 
6.2.1 Model Assumptions 
The underlying assumptions of the mathematical model are: (i) all mass transport and 
polymer swelling/erosion is effectively one-dimensional (i.e. occurs strictly in the            
x direction) since the surface area of the film is orders of magnitude larger than the film 
thickness, (ii) all drug within the film is initially undissolved, (iii) all diffusion can be 













equation based on the Noyes–Whitney equation (Noyes and Whitney, 1897), (v) drug 
particle size is uniform throughout each film cross-sectional layers, but can vary between 
layers (vi) drug particles are initially spherical in shape and retain their spherical shape 
throughout dissolution, (vii) drug and solvent diffusion coefficients can be described by a 
Fujita-type free-volume model, (viii) the total volume of the system is equal to the sum of 
the volumes of drug, solvent, and polymer in the system, (ix) polymer swelling is 
homogenous, (x) polymer dissolution occurs strictly at the surface of the film (x = L) at a 
fixed, linear rate until all polymer is dissolved (xi), no dissolved drug exists at the film-
solvent boundary (i.e. sink conditions), (xii) external mass transfer resistance is 
negligible. 
6.2.2 Mass Balances 
Drug and solvent concentrations throughout the matrix are expressed by Cd(x, t) and 
Cw(x, t) in Equations (6.1) and (6.2), respectively: 
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where Dd and Dw, are the diffusion coefficients of drug and solvent in equilibrium 
swollen polymer, respectively, kd is the drug dissolution rate constant, n is the number of 
drug particles per unit volume film, a is the surface area of a single drug particle, Cs is the 




term of each is the diffusion rate determined by Fick’s second law, and the second term 
of Equation (6.1) describes dissolution of undissolved drug into the dissolved state. The 
diffusivities of drug and solvent, Dd and Dw, are assumed to follow a Fujita-type 
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where i represents either drug or solvent, βi is a constant, and the subscript e indicates an 
equilibrium value in fully swollen polymer. The surface area of a single drug particle, a, 
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where m0 is the mass of a single drug particle and a0 is the initial surface area of a single 
drug particle. The evolution of film thickness, L, can be derived from a total volume 
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where V is the total volume of the system, W and H are the width and height of the film, 
respectively, making up the area perpendicular to all mass transfer, ρd, ρw, and ρp are the 
densities of drug, solvent, and polymer, respectively, Cp0 is the initial polymer 
concentration, Kp is the polymer dissolution rate constant, and t̂  is a dummy variable for 
integration. Since all mass transfer, swelling, and erosion are assumed to occur in the x 
direction and the cross-sectional area does not change with time, this reduces to Equation 
(6.6): 
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These balance equations are subject to the following initial (Equation (6.8)) and boundary 
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6.2.3 Dimensionless Variables and Parameters 
For the sake of generality regarding numerical results and discussion, all proceeding 
mathematical expressions will be expressed in terms of the dimensionless variables and 
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Since the mathematical model under investigation is a moving boundary problem, a 
front-fixing method was employed. This method was first proposed by Landau (1950) 
and first applied to a finite-difference scheme by Crank (1957). This coordinate 
transformation results in an apparent pseudo-convective (second) term in the transformed 
equations for dimensionless drug ( dC ) and solvent ( wC ) concentrations, given by        
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6.2.4 Numerical Procedure 
Equations (6.11)-(6.14) were solved simultaneously in Matlab
®
 (R2015b, Mathworks) 
using ode15s. Since the above is a system of partial differential equations (PDEs), it 
needed to be reduced to a system of ordinary differential equations (ODEs) in order to be 
solvable using Matlab. This was accomplished using the finite difference approximations 
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where j is an index value indicating a point on the spatial grid y. All calculations were 
performed using double precision values and arithmetic. The total number of grid points 
necessary, 101 for both τ and y, was determined by evaluating the lowest number of 
points that produced results within 0.1% relative error of the results produced with double 
the number of points. The same tolerance of 0.1%, relative and absolute, was employed 
when solving the ODE system. In order to account for the large concentration gradients at 
the solvent boundary during dissolution, spatial points were distributed according to a 
geometric progression rate of 1.0125 so that additional points would be present near the 
solvent boundary. 
 
 Experimental Procedures 6.3
Experimental procedures for viscosity, GF particle size after milling and redispersed from 
films, determination of drug content and uniformity in films, and flow-through cell 






Griseofulvin (GF; Letco Medical, Decatur, AL) was selected as a model 
Biopharmaceutics Classification System (BCS) class II drug. Two different viscosity 
grades of hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV, MW   
~14 kDa; and E4M Premium, MW ~88 kDa; The Dow Chemical Company, Midland, 
MI) served as film-formers. E4M samples were generously donated by The Dow 
Chemical Company. HPMC-E15LV also served as a nanoparticle stabilizer during 
WSMM, along with the surfactant sodium dodecyl sulfate (SDS; Fisher Scientific, 
Pittsburgh, PA). Glycerin (Sigma–Aldrich, St. Louis, MO) was used as a film plasticizer. 
GF particle size reduction was performed by WSMM according to Sub-section 6.3.2.1. 
All other materials were used without further processing. 
6.3.2 Methods 
6.3.2.1 Preparation of GF Nanosuspension. GF nanosuspensions were prepared 
via WSMM using a Netzsch mill (Microcer, Fine Particle Technology LLC, Exton, PA). 
Methods and stabilizer concentrations were selected according to previous optimization 
studies (Bilgili and Afolabi, 2012; Monteiro et al., 2013). The suspensions consisted of 
10% GF dispersed in a stabilizer solution of 2.5% HPMC-E15LV and 0.5% SDS (all w/w 
wrt water). One suspension was milled for 4 min (partially milled) and the other was 
milled for 120 min (equilibrium particle size). For comparison of particle sizes, a third 
suspension of identical composition was also prepared but not run through the mill         
(0 min). A single GF nanosuspension formulation was used across all film formulations, 
as opposed to using different polymer MWs for each film formulation, to ensure 




investigation of the effect of polymer MW in WSMM, readers are referred to Li et al. 
(2016)). This meant that the HPMC-E15LV stabilizer, which adsorbed onto the surface of 
the GF nanoparticles during milling, was present in all film precursors, including those 
that used E4M as film-former. 
6.3.2.2 Preparation of Polymer Solutions and Film Precursor Suspensions. 
Formulations for film-forming polymer solutions and film precursor suspensions are 
listed in Table 6.1. Three of the most critical material film attributes (CMAs) in 
determining drug release rate were selected for analysis based on prior experience: dry 
film thickness (Krull et al., 2016b), film-forming polymer molecular weight (MW) (see 
Sub-section 4.3.3.3), and drug particle size (Krull et al., 2016b). Polymer and plasticizer 
concentrations for polymer solutions were selected in such a way that all resulting film 
precursor formulations would be castable but not spread during drying (target viscosity 
range of 5,000-12,000 cP). This was accomplished using a viscosity matching approach 
for polymer solution preparation outlined in Sub-section 4.2.2.2 for the polymer 
solutions, represented by 0’s in Table 6.1. E15 and E4M concentrations in the mixed 
formulation (B) were selected such that each polymer would contribute roughly equally 
to the viscosity of the combined polymer solution. Polymer solutions were prepared by 
adding the appropriate amounts of HPMC and plasticizer to water at 90 ºC, after which 
the solution was allowed to cool to room temperature under continuous magnetic stirring. 
Polymer solutions were mixed with GF nanosuspensions in a 2:1 ratio by mass using a 
Thinky ARE-310 planetary centrifugal mixer (Thinky, Laguna Hills, CA) at 2,000 rpm 




suspensions. If bubbles were still present in the precursor suspension after mixing, the 
precursor was left overnight to settle before casting. 























A0 E15 N/A N/A N/A 18.8% 0.0% 6.3% N/A 12,910 
B0 Mix* N/A N/A N/A   8.2% 1.5% 3.2% N/A 22,590 
C0 E4M N/A N/A N/A   0.0% 3.4% 1.1% N/A 20,420 
A1-50 E15      160    500 2.9% 10.7% 0.0% 3.3% 0.06%   4,610 
A1-100 E15      160 1,000 2.9% 10.7% 0.0% 3.3% 0.06%   4,610 
A1-150 E15      160 1,500 2.9% 10.7% 0.0% 3.3% 0.06%   4,610 
B1-50 Mix*      160    800 2.9%   6.2% 1.0% 2.1% 0.06%   8,190 
B1-100 Mix*      160 1,500 2.9%   6.2% 1.0% 2.1% 0.06%   8,190 
B1-150 Mix*      160 2,700 2.9%   6.2% 1.0% 2.1% 0.06%   8,190 
C1-50 E4M      160 1,550 2.9%   0.0% 2.9% 0.7% 0.06% 11,550 
A2-50 E15      630    500 2.9% 10.7% 0.0% 3.3% 0.06%   4,110 
A2-100 E15      630 1,000 2.9% 10.7% 0.0% 3.3% 0.06%   4,110 
A2-150 E15      630 1,550 2.9% 10.7% 0.0% 3.3% 0.06%   4,110 
B2-50 Mix*      630    800 2.9%   6.2% 1.0% 2.1% 0.06%   5,440 
C2-50 E4M      630 1,550 2.9%   0.0% 2.9% 0.7% 0.06%   7,270 
A3-50 E15 15,000    500 2.9% 10.7% 0.0% 3.3% 0.06%   5,560 
A3-100 E15 15,000 1,150 2.9% 10.7% 0.0% 3.3% 0.06%   5,560 
A3-150 E15 15,000 1,550 2.9% 10.7% 0.0% 3.3% 0.06%   5,560 
B3-50 Mix* 15,000    800 2.9%   6.2% 1.0% 2.1% 0.06%   6,240 
C3-50 E4M 15,000 1,550 2.9%   0.0% 2.9% 0.7% 0.06%   7,400 
*Mix refers to an equal viscosity mixture of E15 and E4M 
 
6.3.2.3 Preparation of GF Nanoparticle-Laden Films. Film precursor suspension 
was manually cast onto a stainless steel substrate with a doctor blade (Elcometer, MI) at 
varying thickness according to Table 6.1 such that 50, 100, and 150 film formulations 
would be approximately 50, 100, and 150 μm in dry thickness, respectively. Wet films 
were then dried in the convective zone of a Lab-Cast Model TC-71LC Tape Caster  




(Davé et al., 2014). The films were peeled from the substrate after drying and stored in 
individual sealed plastic bags for characterization. 
 
 Results and Discussion 6.4
6.4.1 System Parameters and Film Properties 
In order to accurately predict the dissolution performance of a given film, several system 
parameters and film properties must be identified. System parameters for the various 
components used in this study are shown in Table 6.2. These values were used in all 
model calculations (with the exception of kd which will be explained in Section 6.4.3). In 
terms of film properties, some are fixed based on formulation (e.g. polymer MW and 
initial polymer concentration) while others must either be confirmed or measured       
(e.g. drug mass per unit area, dry film thickness, and drug particle size). These properties 





Table 6.2 System Parameters 
Component Type Property Symbol Value Unit Reference 
Griseofulvin Drug 
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for Equation (6.3) 











SDS in water 
Solvent 
Diffusion coefficient 






Masaro et al. 
(1999) 
5.4 mg/ml 
SDS in water 








for Equation (6.3)* 
βw 2.0 - - 
HPMC in 
water 
Polymer Density ρp 1.29 g/cm
3
 Dow (2002) 
*Values taken for water assuming 5.4 mg/ml SDS solution behaves similarly to water 
 





















A1-50 14,167      161   44.5 0.74 2.71 
A1-100 14,167      162   82.2 1.74 6.33 
A1-150 14,167      154 126.3 2.50 9.10 
B1-50 63,410      161   49.9 1.35 3.35 
B1-100 63,410      160   96.3 2.73 6.77 
B1-150 63,410      160 129.8 3.79 9.39 
C1-50 87,800      156   52.0 2.33 2.33 
A2-50 14,167   1,804   35.8 0.67 2.45 
A2-100 14,167   1,535   89.4 1.58 5.74 
A2-150 14,167   2,179 117.9 2.50 9.11 
B2-50 63,410   5,492   48.6 1.31 3.25 
C2-50 87,800 26,714   68.1 2.94 2.94 
A3-50 14,167 13,608   39.9 0.69 2.53 
A3-100 14,167 15,115   90.1 1.73 6.30 
A3-150 14,167 10,695 132.7 2.73 9.94 
B3-50 63,410   9,464   54.1 1.37 3.40 




Other parameters, such as Cwe and Kp0, were expected to be dependent on the MW 
of the film-forming polymer. This is due to the fact that higher MW HPMC exhibits 
significantly more swelling and erodes more slowly when exposed to solvent. To account 
for these phenomena, these parameters were fitted to experimental dissolution data for 
films incorporating GF particles milled to an equilibrium median size of ~160 nm 
(denoted by a 1 in Table 6.3). The resulting relationships are expressed in Equation (6.17) 
and Equation (6.18), respectively: 
 
  63.40 10 0.652weC MW      (6.17) 
 
  11 60 3.84 10 3.52 10pK MW         (6.18) 
 
6.4.2 Influence of System Parameters 
In order to assess the capability of the mathematical model to capture changes in relevant 
system parameters, a sensitivity analysis was performed in which nine parameters were 
adjusted above and below a base value to observe their impact on the release profiles of 
poorly water-soluble drug particle-laden polymer films (Figure 6.2). The base values 
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Figure 6.2 Predicted impact of the following system parameters on release profiles of 
poorly water-soluble drug particle-laden polymer films based on the mathematical model:  
(a) CS, (b) Sd0, (c) L0, (d) Dde, (e) Dwe, (f) Cp0, (g) Cwe, (h) kd, and (i) d50. Bold lettered 
values in each legend are based on formulation A1-100. 
 
Figure 6.2a reveals an expected trend of slower predicted dissolution for less 
soluble drug (CS). Specifically, below a critical solubility, drug particle dissolution 
becomes the dominant release mechanism, resulting in a dramatic decrease in predicted 
release rate. Interestingly, initial undissolved drug concentration (Sd0) did not appear to 
have a significant impact on rate of drug release (Figure 6.2b). This was partially due to 
the fact that, above a critical loading, the polymer film is likely to erode away entirely 
before the drug particles have dissolved, fully exposing the previously embedded drug 




the highest drug loading shown in Figure 6.2b exceeds what can be practically achieved 
in films (more than three times initial polymer concentration) and is simply shown as an 
extreme example. Figure 6.2c revealed the expected trend that increasing initial film 
thickness (L0) leads to a roughly proportional increase in predicted total release time. The 
slight dip in dissolution rate observed in the dissolution profile predicted for the thickest 
film is likely the result of additional time required for complete swelling, as the 
dissolution rate picks up again after the solvent concentration throughout entire film 
reaches Cwe. Faster predicted drug release can be observed with increasing Dde in Figure 
6.2d, as drug diffusion occurs fast enough to no longer limit the rate of drug release. 
Increasing the rate of solvent diffusion (Dwe) also led to faster predicted drug release 
(Figure 6.2e), although this change was not as significant considering the system under 
investigation (HPMC) is hygroscopic and known to absorb water relatively quickly. The 
initial delay in drug release for the lowest Dwe value is indicative of an induction period 
where sufficient solvent necessary for steady-state drug particle dissolution and diffusion 
through the polymer matrix has not yet been achieved. Since the sole contribution of 
polymer is to serve as a fixed mass eroding away at a fixed rate, Cp0 is only expected to 
contribute to the thickness change of the film. As such, Cp0 predictably had little impact 
on the predicted rate of drug release in Figure 6.2f. Increasing equilibrium solvent 
concentration (Cwe) led to slower predicted drug release in Figure 6.2g. This decrease was 
likely due to the increase in solvent absorption capacity of the film and increased polymer 
swellability, since the embedded poorly water-soluble drug particles already have 
sufficient solvent to dissolve, even at low solvent concentrations. For comparison, the 




Cwe = 0.35, effectively doubling its total release time. As seen in Figure 6.2h, increasing 
drug dissolution rate (kd) led to an expected increase in predicted drug release rate. 
Finally, increasing median drug particle size led to a significant decrease in predicted 
drug release rate (Figure 6.2i), as one would expect when drug particle dissolution is 
governed by the Noyes–Whitney equation. Overall, the results of the sensitivity analysis 
are in line with their defining principles and demonstrate the capability of accurately 
capturing the expected behavior of different systems. 
 
6.4.3 Comparison with Experimental Results 
6.4.3.1 Model Comparisons with Formulations for Model Development. 
Comparison of experimentally determined dissolution profiles for the formulations 
shown in Table 6.3 and their respective mathematical model predictions are shown in 
Figure 6.3, Figure 6.4, and Figure 6.5. Despite originally varying between 90-110% 
expected drug release (most likely due to experimental error regarding assessment of 
drug content), all dissolution profiles were normalized to 100% drug release for the sake 
of comparison. It should be noted that kd had to be varied between formulations based on 




, and    
0.116 cm/s for 1, 2, and 3 formulations, respectively). For consistency, these values were 
fit to the experimental data under the assumption that the drug particles released from the 
film were the same size as those in the nanosuspension from which they were taken     
(d50 values of 0.164, 0.555, and 17.470 μm, respectively). This is in contrast to the 
presented model predictions that were calculated taking the size of the drug particles 














































































Figure 6.3 Comparison of experimentally determined dissolution rates from HPMC-E15 
formulations and numerically predicted dissolution profiles for the same formulations.   
kd = 2.91×10
-4
 cm/s for A1 formulations, kd = 4.36×10
-3
 cm/s for A2 formulations, and   






































































Figure 6.4 Comparison of experimentally determined dissolution rates from HPMC-
E15/E4M mixture formulations and numerically predicted dissolution profiles for the 
same formulations. kd = 2.91×10
-4
 cm/s for B1 formulations, kd = 4.36×10
-3
 cm/s for    































































Figure 6.5 Comparison of experimentally determined dissolution rates from HPMC-E4M 
formulations and numerically predicted dissolution profiles for the same formulations.   
kd = 2.91×10
-4
 cm/s for C1-50, kd = 4.36×10
-3
 cm/s for C2-50, and kd = 0.116 cm/s for 
C3-50. 
 
Overall, the mathematical model appeared to fit the experimental dissolution 
profiles reasonably well, typically within the range of experimental error. The expected 
sigmoidal shape was apparent in all predicted curves, with the exception of the unmilled 




increasing film thickness in all applicable cases (all As and B1), in line with previous 
work (Krull et al., 2016b). The model was able to successfully predict slower release 
from thicker films, demonstrating the ability to account for changing film thickness. 
Slower drug release was generally observed with increasing film-forming polymer 
molecular weight, in line with the dissolution results from Sub-section 4.3.3.3. The 
mathematical model was able to account for this as well by establishing linear 
relationships between Cwe, Kp0, and HPMC MW (Equation (6.17) and Equation (6.18), 
respectively). The most apparent shortcoming of the mathematical model was its 
underestimation of the dissolution rate of GF particles larger than a few hundred nm. This 
result was rather unexpected considering extensive work supporting faster solubilization 
and dissolution of nanoparticles relative to microparticles due to the increase in surface 
area-to-volume ratio (Hu et al., 2004; Thorat and Dalvi, 2012). Previous work also 
observed a noticeable decrease in GF release rate from films with increasing particle size 
(Krull et al., 2016b). It is possible that the solubilization effect of SDS in the dissolution 
media negated the anticipated impact of drug particle size on dissolution, resulting in the 
necessity to drastically increase kd to match the experimentally determined dissolution 
profiles. 
The slower-than-observed release predicted for formulations B2-50 and C2-50 
was likely due to the unusually high d50 values measured when the GF nanoparticles for 
those films were redispersed in water. Since the objective of the redispersion technique 
was employed to assess the ability to recover the embedded drug particles in water, it is 
not unexpected that this technique will sometimes fail to accurately reflect the conditions 




The slower-than-observed release predicted for A1-50, A2-50, B2-50, and C1-50 
formulations might be explained by film disintegration, a prevalent phenomenon in thin 
films not explained by diffusion or dissolution. Below ~50 μm in thickness, the HPMC-
based films are prone to physically break apart or disintegrate, leading to accelerated drug 
release due to the massive increase in film surface area exposed to solvent. 
6.4.3.2 Model Comparisons with Formulations from Chapter 4. In order to test 
the predictive capabilities of the dissolution model, the model was used to predict the 
dissolution rate of films from the polymer molecular weight study in Chapter 4. 
Properties of the films used as input parameters for the model can be found in Table 6.4. 
A comparison of the experimentally determined dissolution profiles for these films and 
direct comparisons to their respective predicted dissolution profiles can be found in 
Figure 6.6. The dissolution model proved to be a reasonable fit for all E15 and E50 films, 
even without modifying kd. However, it was necessary to change kd in order to achieve 
reasonable fits for E4M films, although these changes were very slight (within 50%) in 
comparison to those necessary in Sub-section 6.4.3.1. The slower-than-expected release 
from E4M films relative to the model prediction may be attributed to stronger interaction 
between GF nanoparticles and high MW polymer (E4M) compared to lower MW 
polymer (E15 and E50), as noted in Section 5.3.6. That said, comparison with 
experimental data from Chapter 4 demonstrates that the model was able to successfully 


























E15-Low 14,167 168   91.6 1.82 6.62 
E15-Med 14,167 167 114.2 2.14 8.77 
E15-High 14,167 168 110.6 1.93 8.77 
E50-Low 21,000 151   70.4 1.78 4.82 
E50-Med 21,000 152   64.7 1.64 3.96 
E50-High 21,000 148   74.5 1.81 5.40 
E4M-Low 87,800 291   34.7 1.97 1.97 
E4M-Med 87,800 191   41.4 2.02 2.19 
E4M-High 87,800 187   38.5 1.93 2.32 
 
Time (min)









































































Figure 6.6 Comparison of experimentally determined dissolution rates from films loaded 
with GF nanoparticles containing different HPMC MWs and concentrations and 
numerically predicted dissolution profiles for the same formulations.                               
kd = (a,b,d,e,g,h) 2.9×10
-4
 cm/s, (c) 1.7×10
-4







6.4.3.3 Model Comparisons with Formulations from Chapter 5. In order to 
further test the predictive capabilities of the dissolution model, the model was used to 
predict the dissolution rate of films from the drug loading study in Chapter 5. Properties 
of the films used as input parameters for the model can be found in Table 6.5. A 
comparison of the experimentally determined dissolution profiles for E15 films from this 
study and direct comparisons to their respective predicted dissolution profiles can be 
found in Figure 6.7, while the same for E4M films can be found in Figure 6.8. The 
dissolution model was a suitable fit for low loading E15 films, but required kd steadily 
decrease with increasing drug loading (down to 10% its original value for DL6-15,        
49 wt% GF). A similar decrease in kd was also necessary for E4M films up to DL3-4M. 
Potential sources for these discrepancies are difficult to identify due to the number of 
parameters changing simultaneously as the WSMM nanosuspension loading and 
polymer-to-nanosuspension mixing ratio were varied to prepare films with different drug 
loadings (Table 5.1). These differences may be due in part to the fact that, for high drug 
loading films, the model predicted complete erosion of the polymer matrix before all of 
the drug particles had dissolved due to the significant increase in drug-to-polymer ratio. 
This prediction anticipated complete release of undissolved drug particles into the bulk 
solvent and unhindered dissolution, leading to predicted drug release that was faster than 
observed. Since drug release from high loading E4M films was likely the result of 
disintegration into slowly dissolving polymer–drug agglomerates rather than simple 
dispersion the embedded GF nanoparticles (Section 5.3.6), the dissolution model severely 
under-predicted drug release rates from those films based on the size of the agglomerates, 








for DL4-4M and DL5-4M, respectively). This did not come as a surprise, as the 
diffusion–dissolution model was not developed to predict molecular level interaction 
between film components. That said, dissolution model predictions for the drug loading 
study films exposed a potential flaw in the current form of the model, which over-
predicts drug release rates from films that erode before all of the embedded drug particles 
have dissolved. 





















DL1-15 14,167        165   97.2 1.22 7.79 
DL2-15 14,167        171   85.1 2.22 6.19 
DL3-15 14,167        171 109.0 3.18 9.18 
DL4-15 14,167        192 108.8 5.29 8.52 
DL5-15 14,167        164 122.9 6.08 9.91 
DL6-15 14,167        172 127.4 8.61 8.70 
DL1-4M 87,800        161   27.8 1.18 1.88 
DL2-4M 87,800        170   40.1 2.87 2.33 
DL3-4M 87,800        205   45.6 3.50 2.56 
DL4-4M 87,800   44,705   57.3 5.54 2.49 





























































Figure 6.7 Comparison of experimentally determined dissolution rates from HPMC-E15 
formulations with varying GF loading and numerically predicted dissolution profiles for 
the same formulations. kd = (a,b) 2.9×10
-4
 cm/s, (c) 1.9×10
-4
 cm/s, (d) 5.8×10
-5
 cm/s,     
(e) 6.5×10
-5



























































Figure 6.8 Comparison of experimentally determined dissolution rates from HPMC-E4M 
formulations with varying GF loading and numerically predicted dissolution profiles for 
the same formulations. kd = (a) 1.3×10
-4
 cm/s, (b) 6.5×10
-5
 cm/s, (c) 4.8×10
-5
 cm/s,       
(d) 1.2×10
-2





The objective of this work was to develop a mathematical model based on first principles 
that would be able to predict the rate of drug release from polymer films with embedded 
poorly water-soluble drug nanoparticles. The model simultaneously tracked dissolved 
drug concentration, solvent concentration, undissolved drug particle size, and film 
thickness as a function of time throughout the dissolution process. The moving film–
solvent boundary was fixed via coordinate transformation and the resulting coupled 
system of ODEs was solved numerically. Property-dependent relationships were 
developed for system parameters such as Cwe and Kp0 based on experiments used to 




size on drug release and subsequently incorporated into the model. When compared to 
experimentally determined dissolution profiles from previous chapters, dissolution model 
predictions were reasonably close to the observed release rates. Some aspects of the 
model, including under-prediction of the dissolution rate of large drug particles and over-
prediction of the dissolution rate of high drug-to-polymer films, require further 
refinement before application to more general systems. That said, the dissolution model 
demonstrated the ability to react predictably to changes in system parameters, simulate 
the expected shape of the dissolution profile, and flawlessly reflect changes in film 





7 OVERALL CONCLUSIONS AND FUTURE WORK___ 
 
 Overall Conclusions 7.1
In the preceding chapters, the robustness and versatility of polymer strip films as a 
delivery platform for poorly water-soluble drug nanoparticles were demonstrated. The 
relationships elucidated by these studies were then used to develop a mathematical model 
to predict the rate of drug release from such films based on several film CMAs. 
The robustness of the polymer strip film format was demonstrated in Chapter 2 by 
incorporating nanoparticles of five different BCS class II drugs (FNB, GF, NPX, PB, and 
AZD) into films for fast dissolution. Good content uniformity, nanoparticle 
redispersibility, and similar release rates were observed from films regardless of the 
changes in properties across the five drugs, suggesting the film format is capable of 
stabilizing and delivering a wide variety of poorly water-soluble drugs. In addition, these 
advantages were maintained even after surfactant was removed from the formulation, 
which was previously thought to be necessary in order to achieve good nanoparticle 
redispersibility and fast dissolution. This suggests that polymer strip films may also serve 
as a truly surfactant-free delivery platform for poorly water-soluble drugs without 
sacrificing enhanced dissolution or good drug content uniformity. The ability to 
predictably adjust film mechanical properties by changing plasticizer concentration in 
films without impacting drug dissolution rate was demonstrated in Chapter 3. 
Conversely, the ability to predictably adjust drug dissolution rate from films by changing 




minimal impact on film mechanical properties was demonstrated in Chapter 4. Together, 
plasticizer concentration and film-forming polymer MW offer a unique combination of 
easily changed film formulation properties that can be used to tailor final product 
qualities such as film mechanical properties and drug dissolution rates for specific 
applications without negatively impacting the advantages of the strip film format. 
Chapter 5 demonstrated the capability of the strip film format to stabilize and deliver 
poorly water-soluble drug nanoparticles up to 50 wt% drug in the dry film, challenging 
the prior misconception that drug loading in films was severely limited. Finally, a 
mathematical model was developed in Chapter 6 to predict the rate of drug release from 
drug particle-laden polymer films based on many of the film properties investigated in 
the preceding chapters. 
Chapter 1 discussed the relative infancy of the polymer strip film format 
regarding delivery of poorly water-soluble drug nanoparticles, the need for further 
formulation development to investigate the robustness and versatility of the platform, and 
a lack of fundamental understanding regarding how those formulation aspects impact 
film properties. In response, this dissertation work explored all aspects of film 
formulation, including film-forming polymer, plasticizer, drug stabilizer, and the drug 
itself, in an effort to determine the effect each has on the product quality of the resulting 
film. In addition, the impact of each formulation aspect on the rate of drug release from 
films was used to develop a predictive mathematical model. The knowledge gained from 
this work will be instrumental in developing strip films containing poorly water-soluble 




changed to have predictable effects on various critical quality attributes of the resulting 
films. 
 Future Work 7.2
7.2.1 Thick Films for Buccal Delivery and Composite Films for Controlled 
Delivery of Multiple Drugs 
All of the films in this work were designed for oral use, generally for oral dispersion and 
fast release. While the effect of controlled changes in film thickness on dissolution rate 
was investigated in part in Chapter 6, no films in this work were above 130 μm in 
thickness. One simple extension would be to develop thicker films for buccal delivery. 
These films would be designed to adhere to the buccal mucosa in the mouth for the drug 
to permeate through, directly entering the blood stream. Another natural extension of thin 
films would be to stack several films together to form a composite film. These composite 
films could be prepared using different film-forming polymers in each layer for more 
precise control of drug release or containing different drugs in each layer. 
7.2.2 Dissolution Model Expansion to Account for Other Types of Polymers 
The dissolution model developed in Chapter 6 was centered on HPMC, a swellable 
hydrophilic polymer that demonstrated relatively constant dissolution over time. As a 
result, constant polymer dissolution from the film surface until all polymer had dissolved 
was assumed with no observed negative impact on the ability to match experimentally 
determined dissolution profiles. However, not all polymers behave the same way. Some 
exhibit homogenous dissolution where the entire matrix dissolves simultaneously rather 
than just the film surface. In specific cases, polymers may be broken into two distinct 




different properties. Accounting for these types of polymers in the dissolution model will 
require tracking of polymer concentration throughout the film, as well as the potential 
swelling front separating the glassy and rubbery regions. 
7.2.3 Mathematical Model for Prediction of Drying Rate from Drug Particle-
loaded Polymer Films 
While the focus of this dissertation has been on the impact of film formulation on product 
quality, scale-up of processing techniques will be an important task for future efforts. 
One process in particular that has a significant impact on the quality of the resulting film 
is drying. Not only does the film need to dry within a sufficiently brief amount of time to 
be considered economically feasible, but the residual solvent content and drug particle 
morphology must be carefully controlled. To this end, a numerical drying model may be 
developed to predict changes in the amount of solvent, temperature, and solvent weight 
fraction profiles of the drying film over time based on first principles. This model should 
account for heating by conduction, convection, and potentially radiation, as well as time-
varying film thickness. The resulting predictions can be used to optimize the film drying 
process to produce adequately dried films that exhibit desirable product qualities in the 





APPENDIX A DISSOLUTION PROFILE COMPARISON________________ 
 
Pairwise comparison of dissolution profiles was performed using similarity and 
difference factors as described by Boateng et al. (2012) and Costa and Lobo (2001). 
Since difference factors are dependent on which of the two curves is used as a reference, 
both possible values of f1 are presented as f1a and f1b for each pair of dissolution profiles. 
Pairs that exhibit f1 < 15 and f2 > 50 are considered statistically similar. 
 
 Effect of Plasticizer A.1 
f1 and f2 values for comparison of dissolution profiles of fresh films are shown in Table 
A.1. The same for each of the seven film formulations after 0, 3, and 6 months of storage 





Table A.1 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of Fresh Films Loaded with GF Nanoparticles 
2.5% 
Glycerin 
f1a   2.7      
f1b   2.3      
f2 88.3      
5.0% 
Glycerin 
f1a   5.5   6.5     
f1b   6.2   8.5     
f2 72.9 68.0     
2.5% 
Triacetin 
f1a 19.6 17.8 17.0    
f1b 22.7 23.7 17.4    
f2 46.6 45.3 52.9    
5.0% 
Triacetin 
f1a 13.3 13.2   9.0   8.9   
f1b 11.8 13.5   7.1   6.9   
f2 58.4 56.0 67.5 66.4   
2.5% PEG 
f1a 27.9 24.9 27.0 12.5 15.0  
f1b 34.9 36.0 29.8 13.5 21.2  
f2 36.1 35.4 39.8 56.4 46.8  
5.0% PEG 
f1a   6.1   5.0 11.4 26.4 16.9 37.3 
f1b   4.8   4.5   7.9 17.9 15.0 23.4 
f2 71.4 76.1 60.7 43.5 51.9 34.7 













Table A.2 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of Films Loaded with GF Nanoparticles Containing No Plasticizer Immediately 
after Film Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months 
of Storage at 40 ºC, 75% RH 
3 months 
f1a   3.8  
f1b   3.7  
f2 80.7  
6 months 
f1a 10.2   7.3 
f1b 11.0   8.1 
f2 62.4 69.7 







Table A.3 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of 2.5% Glycerin Films Loaded with GF Nanoparticles Immediately after Film 
Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months of Storage 
at 40 ºC, 75% RH 
3 months 
f1a 21.1  
f1b 26.9  
f2 42.4  
6 months 
f1a 23.1   8.5 
f1b 34.2   9.9 
f2 36.3 62.6 
2.5% Glycerin  Fresh 3 months 
 
Table A.4 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of 5.0% Glycerin Films Loaded with GF Nanoparticles Immediately after Film 
Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months of Storage 
at 40 ºC, 75% RH 
3 months 
f1a   5.5  
f1b   4.5  
f2 75.8  
6 months 
f1a 22.6 16.7 
f1b 26.3 24.0 
f2 42.9 45.4 
5.0% Glycerin  Fresh 3 months 
 
Table A.5 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of 2.5% Triacetin Films Loaded with GF Nanoparticles Immediately after Film 
Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months of Storage 
at 40 ºC, 75% RH 
3 months 
f1a 22.1  
f1b 33.1  
f2 39.0  
6 months 
f1a 11.5 21.3 
f1b 12.6 15.5 
f2 58.5 49.2 






Table A.6 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of 5.0% Triacetin Films Loaded with GF Nanoparticles Immediately after Film 
Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months of Storage 
at 40 ºC, 75% RH 
3 months 
f1a 16.3  
f1b 18.9  
f2 49.3  
6 months 
f1a   8.0 10.1 
f1b 10.3 11.2 
f2 62.8 62.2 
5.0% Triacetin  Fresh 3 months 
 
Table A.7 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of 2.5% PEG Films Loaded with GF Nanoparticles Immediately after Film 
Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months of Storage 
at 40 ºC, 75% RH 
3 months 
f1a 10.0  
f1b 11.5  
f2 61.3  
6 months 
f1a   4.5   7.3 
f1b   4.4   6.2 
f2 76.5 66.6 
2.5% PEG  Fresh 3 months 
 
Table A.8 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of 5.0% PEG Films Loaded with GF Nanoparticles Immediately after Film 
Preparation, after 3 Months of Storage at 40 ºC, 75% RH, and after 6 Months of Storage 
at 40 ºC, 75% RH 
3 months 
f1a 17.4  
f1b 25.8  
f2 43.2  
6 months 
f1a 16.3   3.3 
f1b 24.6   3.4 
f2 44.5 84.3 






 Effect of Film-Forming Polymer Molecular Weight A.2 
f1 and f2 values for comparison of dissolution profiles are shown in Table A.9. 
Table A.9 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of HPMC Films Loaded with GF Nanoparticles 
E15-Med 
f1 44.0        
f1 27.4        
f2 33.9        
E15-High 
f1 41.2 4.8       
f1 24.9 4.7       
f2 35.6 77.4       
E50-Low 
f1 10.1 29.6 26.5      
f1 7.6 35.6 32.9      
f2 64.0 37.8 39.4      
E50-Med 
f1 10.3 29.0 25.6 3.7     
f1 6.9 31.1 28.5 3.3     
f2 62.4 39.5 41.4 83.2     
E50-High 
f1 24.8 16.0 12.4 18.4 15.2    
f1 14.9 15.5 12.4 14.8 13.7    
f2 45.0 54.7 58.2 51.8 54.1    
E4M-Low 
f1 72.9 50.5 51.9 68.8 66.5 58.3   
f1 22.3 24.7 26.3 28.0 30.3 29.5   
f2 22.7 29.9 28.7 22.6 22.3 26.2   
E4M-Med 
f1 63.8 35.9 37.9 58.9 56.0 45.8 16.6  
f1 19.7 17.8 19.5 24.3 25.8 23.5 16.8  
f2 25.7 37.0 35.4 26.3 26.3 31.7 53.2  
E4M-High 
f1 59.8 33.9 35.9 56.1 53.3 43.6 18.7 4.2 
f1 20.2 18.4 20.1 25.3 26.9 24.5 20.7 4.6 


















 Effect of Drug Loading A.3 
f1 and f2 values for comparison of dissolution profiles of fresh films are shown in Table 
A.10. The same for E15 and E4M films after 0, 3, and 6 months of storage at 40 ºC,   





Table A.10 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of Fresh HPMC Films with Different GF Nanoparticle Loadings 
DL2-15 
f1 3.6          
f1 3.6          
f2 81.7          
DL3-15 
f1 38.1 39.1         
f1 22.1 23.2         
f2 34.7 34.6         
DL4-15 
f1 70.9 71.4 49.4        
f1 19.9 20.4 23.9        
f2 21.3 21.3 29.2        
DL5-15 
f1 71.8 72.4 51.5 2.7       
f1 22.3 22.9 27.5 3.0       
f2 20.8 20.8 28.1 86.6       
DL6-15 
f1 85.3 85.6 75.0 43.3 44.0      
f1 19.8 20.2 29.9 35.8 32.8      
f2 17.3 17.3 19.9 32.0 32.5      
DL1-4M 
f1 51.0 51.9 20.3 21.5 25.7 36.5     
f1 21.4 22.2 14.6 32.2 34.8 66.1     
f2 28.9 28.8 48.6 38.5 36.7 22.4     
DL2-4M 
f1 82.2 82.5 65.7 20.0 20.5 21.2 51.8    
f1 26.1 26.7 35.8 22.6 20.9 29.0 39.1    
f2 18.3 18.3 23.1 49.1 50.2 42.9 28.2    
DL3-4M 
f1 89.1 89.3 80.4 52.6 53.3 12.1 72.5 40.3   
f1 21.8 22.2 33.8 45.8 41.8 12.8 42.2 31.0   
f2 16.4 16.4 18.5 27.9 28.5 62.7 20.4 36.2   
DL4-4M 
f1 88.8 89.0 81.0 54.6 55.3 15.4 73.9 42.6 4.0  
f1 19.5 20.0 30.6 42.7 39.1 14.6 38.7 29.5 3.6  
f2 16.4 16.4 18.2 27.0 27.6 58.0 20.0 35.0 83.2  
DL5-4M 
f1 92.7 92.8 86.0 60.3 61.5 19.6 79.7 49.0 8.2 5.1 
f1 21.2 21.7 33.8 49.1 45.3 19.3 43.4 35.4 7.7 5.3 
f2 15.6 15.6 17.0 25.0 25.5 53.4 18.4 32.5 71.5 79.2 

























Table A.11 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of HPMC-E15 Films with Different GF Nanoparticle Loadings after 0, 3, and     
6 Months of Storage at 40 ºC, 75% RH 
Month 
comparisons > 
_DL1-15_ _DL2-15_ _DL3-15_ 
0-3 0-6 3-6 0-3 0-6 3-6 0-3 0-6 3-6 
f1   7.5 15.2 10.3 12.0 18.7 22.7   2.1   9.4   8.5 
f1   8.3 16.2   9.9 10.1 25.0 36.0   2.1 11.4 10.5 
f2 67.0 53.0 62.3 60.2 45.5 37.2 90.9 61.7 63.5 
Month 
comparisons > 
_DL4-15_ _DL5-15_ _DL6-15_ 
0-3 0-6 3-6 0-3 0-6 3-6 0-3 0-6 3-6 
f1 10.3 12.9   4.9 10.3 12.9   4.9 10.3 12.9   4.9 
f1 13.3 17.9   5.2 13.3 17.9   5.2 13.3 17.9   5.2 
f2 56.6 51.5 77.9 56.6 51.5 77.9 56.6 51.5 77.9 
 
Table A.12 Similarity (f2) and Difference (f1) Factors for Comparison of Dissolution 
Profiles of HPMC-E4M Films with Different GF Nanoparticle Loadings after 0, 3, and   
6 Months of Storage at 40 ºC, 75% RH 
Month 
comparisons > 
_DL1-4M_ _DL2-4M_ _DL3-4M_ 
0-3 0-6 3-6 0-3 0-6 3-6 0-3 0-6 3-6 
f1   5.8 21.7 23.5   3.6 25.4 26.1   3.2 29.5 28.1 
f1   5.4 32.0 37.0   3.5 28.5 30.2   3.2 39.1 37.9 




0-3 0-6 3-6 0-3 0-6 3-6 
f1   2.4 28.5 29.8 13.6 31.1 27.2 
f1   2.5 54.0 55.0 14.2 61.3 51.4 
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